{"data":{"filter_options":{"titles":[{"name":"Managing Partner Atlanta Office","value":"Managing Partner Atlanta Office"},{"name":"Partner","value":"Partner"},{"name":"Partner / Head of Pro Bono","value":"Partner / Head of Pro Bono"},{"name":"Partner / Chief Operating Officer","value":"Partner / Chief Operating Officer"},{"name":"Partner / General Counsel","value":"Partner / General Counsel"},{"name":"Partner / Dir. E-Discovery Ops","value":"Partner / Dir. E-Discovery Ops"},{"name":"Partner / Chairman, Saudi Arabia Practice","value":"Partner / Chairman, Saudi Arabia Practice"},{"name":"K\u0026S Talent Partner","value":"K\u0026S Talent Partner"},{"name":"Partner / Chief Human Resources Officer","value":"Partner / Chief Human Resources Officer"},{"name":"Chairman","value":"Chairman"},{"name":"Senior Counsel","value":"Senior Counsel"},{"name":"Associate Director, E-Discovery Operations","value":"Associate Director, E-Discovery Operations"},{"name":"Counsel","value":"Counsel"},{"name":"Senior Associate","value":"Senior Associate"},{"name":"Associate","value":"Associate"},{"name":"Senior Attorney","value":"Senior Attorney"},{"name":"Senior Lawyer","value":"Senior Lawyer"},{"name":"Attorney","value":"Attorney"},{"name":"Senior Counsel and Policy Advisor","value":"Senior Counsel and Policy Advisor"},{"name":"Managing Director - Capital Solutions","value":"Managing Director - Capital Solutions"},{"name":"Senior Government Relations Advisor","value":"Senior Government Relations Advisor"},{"name":"Associate General Counsel","value":"Associate General Counsel"},{"name":"Senior Advisor","value":"Senior Advisor"},{"name":"Patent Agent","value":"Patent Agent"},{"name":"Consultant","value":"Consultant"},{"name":"Government Relations Advisor","value":"Government Relations Advisor"},{"name":"Chief of Lateral Partner Recruiting \u0026 Integration","value":"Chief of Lateral Partner Recruiting \u0026 Integration"},{"name":"Chief Financial Officer","value":"Chief Financial Officer"},{"name":"Chief Information Officer","value":"Chief Information Officer"},{"name":"Chief Revenue Officer","value":"Chief Revenue Officer"},{"name":"Chief Recruiting Officer","value":"Chief Recruiting Officer"},{"name":"Chief Lawyer Talent Development Officer","value":"Chief Lawyer Talent Development Officer"},{"name":"Chief Marketing Officer","value":"Chief Marketing Officer"},{"name":"Tax Consultant","value":"Tax Consultant"},{"name":"Director of Community Affairs","value":"Director of Community Affairs"},{"name":"Director of Facilities \u0026 Admin Operations","value":"Director of Facilities \u0026 Admin Operations"},{"name":"Senior Office Manager","value":"Senior Office Manager"},{"name":"Director of Operations","value":"Director of Operations"},{"name":"Pro Bono Deputy","value":"Pro Bono Deputy"},{"name":"Director of Office Operations","value":"Director of Office Operations"},{"name":"Director of Operations Europe","value":"Director of Operations Europe"},{"name":"Law Clerk","value":"Law Clerk"},{"name":"Deputy General Counsel","value":"Deputy General Counsel"}],"schools":[{"name":"(Commercial Law), in front of Monash University, Australia","value":3045},{"name":"Aberystwyth University","value":3004},{"name":"Albany Law School","value":2118},{"name":"American University Washington College of Law","value":3042},{"name":"American University, Washington College of Law","value":3024},{"name":"Appalachian School of Law","value":2891},{"name":"Ateneo de Manila University","value":2914},{"name":"Ave Maria School of Law","value":2892},{"name":"Baylor University School of Law","value":181},{"name":"Benjamin N. Cardozo School of Law","value":2619},{"name":"Binghamton University","value":3002},{"name":"Boston College Law School","value":245},{"name":"Boston University School of Law","value":247},{"name":"BPP Law School Leeds","value":2642},{"name":"BPP Law School London","value":2782},{"name":"BPP University","value":2984},{"name":"Brooklyn Law School","value":2705},{"name":"Cairo University, Law School","value":2962},{"name":"California Western School of Law","value":315},{"name":"Capital University Law School","value":327},{"name":"Case Western Reserve University School of Law","value":345},{"name":"Cecil C. Humphreys School of Law","value":2235},{"name":"Chapman University School of Law","value":377},{"name":"Charleston School of Law","value":2910},{"name":"City Law School, London","value":2998},{"name":"City Law School","value":2857},{"name":"Clark University","value":3006},{"name":"Cleveland-Marshall College of Law","value":426},{"name":"Columbia University School of International and Public Affairs","value":3008},{"name":"Columbia University School of Law","value":485},{"name":"Columbia University","value":3126},{"name":"Columbus School of Law, Catholic University of America","value":3010},{"name":"Columbus School of Law","value":350},{"name":"Concord Law School of Kaplan University","value":1026},{"name":"Cornell Law School","value":512},{"name":"Creighton University School of Law","value":518},{"name":"Creighton University","value":3025},{"name":"Cumberland School of Law","value":1759},{"name":"CUNY School of Law","value":2893},{"name":"David A. Clarke School of Law","value":2399},{"name":"Deakin University School of Law","value":2907},{"name":"DePaul University College of Law","value":565},{"name":"DePaul University College of Law","value":3060},{"name":"Dickinson School of Law","value":2719},{"name":"Drake University Law School","value":609},{"name":"Duke University School of Law","value":613},{"name":"Duquesne University School of Law","value":614},{"name":"Dwayne O. Andreas School of Law","value":173},{"name":"Edinburgh Law School","value":3160},{"name":"Emory University School of Law","value":659},{"name":"ESADE Business and Law School – Universidad Ramon Llull","value":3215},{"name":"Fachseminare von Fürstenberg","value":2918},{"name":"Faculté Libre de Droit, Université Catholique de Lille","value":3055},{"name":"Faculty of Law, University of Zagreb","value":2983},{"name":"Faculty of Law","value":2944},{"name":"Faculty of Law","value":3039},{"name":"Federal University of Rio de Janeiro","value":3022},{"name":"Federal University of Rio Grande do Sul School of Law (Brazil)","value":3062},{"name":"Florida A\u0026M University College of Law","value":699},{"name":"Florida Coastal School of Law","value":2894},{"name":"Florida International College of Law","value":707},{"name":"Florida State University College of Law","value":720},{"name":"Fordham University School of Law","value":722},{"name":"Franklin Pierce Law Center","value":734},{"name":"Friedrich-Schiller-Universität Jena","value":3015},{"name":"George Mason University School of Law","value":752},{"name":"George Washington University Law School","value":753},{"name":"Georgetown University Law Center","value":755},{"name":"Georgia State University College of Law","value":761},{"name":"Ghent Law School","value":2793},{"name":"Golden Gate University School of Law","value":770},{"name":"Gonzaga University School of Law","value":772},{"name":"Graduate Institute of International and Development Studies, Geneva","value":2997},{"name":"Hamline University School of Law","value":811},{"name":"Harvard Law School","value":824},{"name":"Hebrew University of Jerusalem Faculty of Law","value":2994},{"name":"Hofstra University School of Law","value":858},{"name":"Howard University School of Law","value":872},{"name":"Huazhong University of Science and Technology","value":3016},{"name":"Humboldt University of Berlin","value":3012},{"name":"Indiana University School of Law","value":2711},{"name":"Indiana University School of Law","value":890},{"name":"International Association of Privacy Professionals","value":3009},{"name":"J. Reuben Clark Law School","value":262},{"name":"Jacob D. Fuchsberg Law Center","value":2084},{"name":"James Cook University of North Queensland","value":3034},{"name":"Jean Moulin University Lyon 3, France","value":2938},{"name":"Johns Hopkins Bloomberg School of Public Health","value":2992},{"name":"Justus-Liebig-Universität Gießen Rechtswissenschaft (Germany)","value":3063},{"name":"Kansas City School of Law","value":2247},{"name":"Keio University","value":2968},{"name":"Kent College of Law","value":883},{"name":"Kline School of Law","value":611},{"name":"KU Leuven","value":3007},{"name":"Levin College of Law","value":2189},{"name":"Lewis and Clark Law School","value":1089},{"name":"Liberty University School of Law","value":1094},{"name":"Lincoln College of Law","value":2253},{"name":"LL.M. in International Crime and Justice UNICRI","value":2937},{"name":"Loyola Law School","value":2895},{"name":"Loyola University Chicago School of Law","value":1135},{"name":"Loyola University New Orleans College of Law","value":1136},{"name":"Marquette University Law School","value":1176},{"name":"McGeorge School of Law","value":2402},{"name":"McGill University","value":2659},{"name":"Melbourne Law School","value":2899},{"name":"Mercer University Walter F. George School of Law","value":1221},{"name":"Mexico Autonomous Institute of Technology","value":2996},{"name":"Michael E. Moritz College of Law","value":2728},{"name":"Michigan State University College of Law","value":1245},{"name":"Mississippi College School of Law","value":1285},{"name":"Moscow State University","value":2815},{"name":"National and Kapodistrian University of Athens","value":3032},{"name":"National Law University Jodhpur","value":3020},{"name":"National University of Singapore, Faculty of Law","value":2662},{"name":"New England School of Law","value":2886},{"name":"New York Law School","value":1403},{"name":"New York University School of Law","value":1406},{"name":"Norman Adrian Wiggins School of Law","value":323},{"name":"North Carolina Central University School of Law","value":1417},{"name":"Northeastern University School of Law","value":1430},{"name":"Northern Illinois University College of Law","value":1432},{"name":"Northwestern Pritzker School of Law","value":1451},{"name":"Notre Dame Law School","value":2278},{"name":"Ohio Northern University Law School","value":3036},{"name":"Oklahoma City University School of Law","value":1487},{"name":"Osgoode Hall Law School","value":3124},{"name":"Pace University School of Law","value":1516},{"name":"Panteion University","value":3033},{"name":"Paul M. Hebert Law Center","value":2713},{"name":"Pennsylvania State University, Dickinson School of Law","value":1562},{"name":"Pepperdine University School of Law","value":1570},{"name":"Pettit College of Law","value":1473},{"name":"Pontificia Universidad Catolica de Chile","value":3203},{"name":"Pontificia Universidad Catolica del Peru","value":3011},{"name":"Pontificia Universidad Javeriana","value":3013},{"name":"Pontificia Universidade Catolica de Sao Paulo","value":3095},{"name":"Prince Sultan University College of Law","value":3167},{"name":"Queens College, Cambridge","value":3003},{"name":"Quinnipiac University School of Law","value":1626},{"name":"Ralph R. Papitto School of Law","value":1686},{"name":"Regent University School of Law","value":1649},{"name":"Rice University","value":3043},{"name":"Ruprecht-Karls-Universität Heidelberg","value":3049},{"name":"Rutgers University School of Law-Newark","value":1699},{"name":"Rutgers University School of Law","value":1697},{"name":"S.J. Quinney College of Law","value":2408},{"name":"Saint Louis University School of Law","value":1732},{"name":"Salmon P. Chase College of Law","value":1433},{"name":"Sandra Day O'Connor College of Law","value":103},{"name":"Santa Clara University School of Law","value":1771},{"name":"Seattle University School of Law","value":1787},{"name":"Seton Hall University School of Law","value":1790},{"name":"Shepard Broad Law Center","value":1460},{"name":"South Texas College of Law","value":2721},{"name":"Southern Illinois University School of Law","value":1849},{"name":"Southern Methodist University Dedman School of Law","value":1852},{"name":"Southern University Law Center","value":1857},{"name":"Southwestern Law School","value":1876},{"name":"St. John's University School of Law","value":2724},{"name":"St. Mary's University School of Law","value":1896},{"name":"St. Thomas University School of Law","value":1746},{"name":"Stanford Law School","value":1904},{"name":"Stetson University College of Law","value":1910},{"name":"Sturm College of Law","value":2184},{"name":"Suffolk University Law School","value":1921},{"name":"Syracuse University College of Law","value":1956},{"name":"Temple University Beasley School of Law","value":1974},{"name":"Texas A\u0026M School of Law","value":1980},{"name":"Texas Tech University School of Law","value":1994},{"name":"Texas Wesleyan University School of Law","value":1996},{"name":"The College of Law Australia","value":3091},{"name":"The College of Law, London","value":2935},{"name":"The John Marshall Law School","value":2034},{"name":"The Judge Advocate General's Legal Center and School","value":2896},{"name":"The Ohio State University Moritz College of Law","value":2990},{"name":"The University of Akron School of Law","value":2143},{"name":"The University of Alabama School of Law","value":2045},{"name":"The University of Birmingham, U.K.","value":2796},{"name":"The University of Iowa College of Law","value":2206},{"name":"The University of Texas School of Law","value":2055},{"name":"The University of Tulsa College of Law","value":2407},{"name":"Thomas Jefferson School of Law","value":685},{"name":"Thomas M. Cooley Law School","value":2729},{"name":"Thurgood Marshall School of Law","value":1992},{"name":"Tianjin University of Commerce","value":2995},{"name":"Tulane University Law School","value":2113},{"name":"UC Davis School of Law","value":2160},{"name":"UCLA School of Law","value":2162},{"name":"Universidad Católica de Honduras","value":2916},{"name":"Universidad Francisco Marroquin","value":3090},{"name":"Universidad Panamericana","value":2904},{"name":"Universidad Torcuato di Tella","value":3035},{"name":"Universidade de São Paulo, Faculdade de Direito","value":3028},{"name":"Universidade Presbiteriana Mackenzie","value":2977},{"name":"Università Commerciale Luigi Bocconi","value":3135},{"name":"University at Buffalo Law School","value":1928},{"name":"University College Dublin Law School","value":2900},{"name":"University of Alberta Faculty of Law","value":3088},{"name":"University of Amsterdam","value":2980},{"name":"University of Arizona, James E. Rogers College of Law","value":2149},{"name":"University of Arkansas School of Law","value":2154},{"name":"University of Baltimore School of Law","value":2156},{"name":"University of California College of the Law","value":3196},{"name":"University of California Hastings College of Law","value":2158},{"name":"University of California Irvine School of Law","value":2161},{"name":"University of California, Berkeley, School of Law","value":2159},{"name":"University of California, Davis","value":3019},{"name":"University of Cambridge, U.K","value":2991},{"name":"University of Canterbury","value":2981},{"name":"University of Central Florida","value":3027},{"name":"University of Chester Law School","value":3005},{"name":"University of Chicago Law School","value":2174},{"name":"University of Chicago","value":3038},{"name":"University of Cincinnati College of Law","value":2175},{"name":"University of Colorado School of Law","value":2177},{"name":"University of Connecticut School of Law","value":2180},{"name":"University of Dayton School of Law","value":2182},{"name":"University of Detroit Mercy School of Law","value":2185},{"name":"University of East Anglia","value":3000},{"name":"University of Florida, Levin College of Law","value":3188},{"name":"University of Georgia School of Law","value":2190},{"name":"University of Houston Law Center","value":2197},{"name":"University of Hull","value":3040},{"name":"University of Idaho College of Law","value":2201},{"name":"University of Illinois College of Law","value":2204},{"name":"University of Kansas School of Law","value":2208},{"name":"University of Kentucky College of Law","value":2210},{"name":"University of La Verne College of Law","value":2211},{"name":"University of Law, London","value":2999},{"name":"University of Lethbridge","value":3030},{"name":"University of Louisville Brandeis School of Law","value":2214},{"name":"University of Maine School of Law","value":2391},{"name":"University of Maryland School of Law","value":2224},{"name":"University of Miami School of Law","value":2236},{"name":"University of Michigan Law School","value":2237},{"name":"University of Minnesota Law School","value":2243},{"name":"University of Mississippi School of Law","value":2244},{"name":"University of Missouri School of Law","value":2246},{"name":"University of Montana School of Law","value":2048},{"name":"University of Nebraska College of Law","value":2744},{"name":"University of New Mexico School of Law","value":2262},{"name":"University of North Carolina School of Law","value":2266},{"name":"University of North Dakota School of Law","value":2271},{"name":"University of Oklahoma Law Center","value":2747},{"name":"University of Oregon School of Law","value":2281},{"name":"University of Pennsylvania Law School","value":2282},{"name":"University of Pittsburgh School of Law","value":2354},{"name":"University of Richmond School of Law","value":2370},{"name":"University of San Diego School of Law","value":2377},{"name":"University of San Francisco School of Law","value":2378},{"name":"University of South Carolina School of Law","value":2750},{"name":"University of South Dakota School of Law","value":2387},{"name":"University of Southern California Gould School of Law","value":3051},{"name":"University of St. Thomas School of Law","value":2751},{"name":"University of Sydney Law School","value":3031},{"name":"University of Tennessee College of Law","value":2051},{"name":"University of the West of England, Bristol","value":3001},{"name":"University of Toledo College of Law","value":2406},{"name":"University of Toronto","value":2912},{"name":"University of Utah","value":3026},{"name":"University of Virginia School of Law","value":2410},{"name":"University of Washington School of Law","value":2412},{"name":"University of Wisconsin Law School","value":2419},{"name":"University of Wyoming College of Law","value":2429},{"name":"University of Zürich","value":3037},{"name":"University Paris Dauphine","value":2976},{"name":"University Paris II Assas","value":2975},{"name":"University Paris II Assas","value":3052},{"name":"USC Gould School of Law","value":2389},{"name":"Utrecht University","value":3085},{"name":"Valparaiso University School of Law","value":2441},{"name":"Vanderbilt University School of Law","value":2442},{"name":"Vermont Law School","value":2451},{"name":"Villanova University School of Law","value":2454},{"name":"Wake Forest University School of Law","value":2471},{"name":"Washburn University School of Law","value":2482},{"name":"Washington and Lee University School of Law","value":2484},{"name":"Washington College of Law","value":61},{"name":"Washington University in St. Louis School of Law","value":2489},{"name":"Wayne State University Law School","value":2493},{"name":"West Virginia University College of Law","value":2517},{"name":"Western New England College School of Law","value":2528},{"name":"Western State College of Law","value":2897},{"name":"Wharton School of Business","value":3044},{"name":"Whittier Law School","value":2564},{"name":"Widener University Delaware Law School","value":2569},{"name":"Willamette University College of Law","value":2573},{"name":"William \u0026 Mary Law School","value":462},{"name":"William H. Bowen School of Law","value":2150},{"name":"William Mitchell College of Law","value":2758},{"name":"William S. Boyd School of Law","value":2256},{"name":"William S. Richardson School of Law","value":2195},{"name":"Wilmington University","value":2993},{"name":"Yale Law School","value":2605}],"offices":[{"name":"Abu Dhabi","value":13},{"name":"Atlanta","value":1},{"name":"Austin","value":12},{"name":"Brussels","value":23},{"name":"Charlotte","value":8},{"name":"Chicago","value":21},{"name":"Dallas","value":28},{"name":"Denver","value":22},{"name":"Dubai","value":6},{"name":"Frankfurt","value":9},{"name":"Geneva","value":15},{"name":"Houston","value":4},{"name":"London","value":5},{"name":"Los Angeles","value":19},{"name":"Miami","value":25},{"name":"New York","value":3},{"name":"Northern Virginia","value":24},{"name":"Paris","value":14},{"name":"Riyadh","value":27},{"name":"Sacramento","value":20},{"name":"San Francisco","value":10},{"name":"Silicon Valley","value":11},{"name":"Singapore","value":16},{"name":"Sydney","value":26},{"name":"Tokyo","value":18},{"name":"Washington, D.C.","value":2}],"capabilities":[{"name":"Corporate, Finance and Investments","value":"cg-1"},{"name":"Activist Defense","value":72},{"name":"Capital Markets","value":26},{"name":"Construction and Procurement","value":40},{"name":"Corporate Governance","value":27},{"name":"Emerging Companies and Venture Capital","value":80},{"name":"Employee Benefits and Executive Compensation","value":28},{"name":"Energy and Infrastructure Projects","value":35},{"name":"Financial Restructuring","value":10},{"name":"Fund Finance","value":134},{"name":"Global Human Capital and Compliance ","value":121},{"name":"Investment Funds and Asset Management","value":78},{"name":"Leveraged Finance","value":29},{"name":"Mergers and Acquisitions (M\u0026A)","value":32},{"name":"Middle East and Islamic Finance and Investment","value":31},{"name":"Private Equity","value":33},{"name":"Public Companies","value":126},{"name":"Real Estate","value":36},{"name":"Structured Finance and Securitization","value":82},{"name":"Tax","value":37},{"name":"Technology Transactions","value":115},{"name":"Government Matters","value":"cg-2"},{"name":"Antitrust","value":1},{"name":"Data, Privacy and Security","value":6},{"name":"Environmental, Health and Safety","value":71},{"name":"FDA and Life Sciences","value":21},{"name":"Government Advocacy and Public Policy","value":23},{"name":"Government Contracts","value":116},{"name":"Healthcare","value":24},{"name":"Innovation Protection","value":135},{"name":"International Trade","value":25},{"name":"National Security and Corporate Espionage","value":110},{"name":"Securities Enforcement and Regulation","value":20},{"name":"Special Matters and Government Investigations","value":11},{"name":"Trial and Global Disputes","value":"cg-3"},{"name":"Antitrust ","value":129},{"name":"Appellate, Constitutional and Administrative Law","value":2},{"name":"Bankruptcy and Insolvency Litigation","value":38},{"name":"Class Action Defense","value":3},{"name":"Commercial Litigation","value":5},{"name":"Corporate and Securities Litigation","value":19},{"name":"E-Discovery","value":7},{"name":"Global Construction and Infrastructure Disputes","value":4},{"name":"Innovation Protection","value":136},{"name":"Intellectual Property","value":13},{"name":"International Arbitration and Litigation","value":14},{"name":"Labor and Employment","value":15},{"name":"Product Liability","value":17},{"name":"Professional Liability","value":18},{"name":"Toxic \u0026 Environmental Torts","value":16},{"name":"Industries / Issues","value":"cg-4"},{"name":"Artificial Intelligence (AI) and Machine Learning","value":133},{"name":"Automotive, Transportation and Mobility","value":106},{"name":"Buy American","value":124},{"name":"Crisis Management","value":111},{"name":"Doing Business in Latin America","value":132},{"name":"Energy Transition","value":131},{"name":"Energy","value":102},{"name":"Environmental Agenda","value":125},{"name":"Environmental, Social and Governance (ESG)","value":127},{"name":"Financial Services","value":107},{"name":"Focus on Women's Health","value":112},{"name":"Food and Beverage","value":105},{"name":"Higher Education","value":109},{"name":"Life Sciences and Healthcare","value":103},{"name":"Russia/Ukraine","value":128},{"name":"Special Purpose Acquisition Companies (SPACs)","value":123},{"name":"Technology","value":118}]},"title_id":null,"school_id":null,"office_id":null,"capability_id":"23","extra_filter_id":null,"extra_filter_type":null,"q":null,"starts_with":"R","per_page":12,"people":[{"id":432953,"version":1,"owner_type":"Person","owner_id":986,"payload":{"bio":"\u003cp\u003eNikki Reeves is an FDA and healthcare regulatory compliance lawyer with more than 25\u0026nbsp;years of experience.\u0026nbsp; Nikki co-chairs the firm's Government Matters \u0026amp; Regulatory practice management group, which is comprised of 200+ lawyers and consultants in eight practice areas.\u0026nbsp; Nikki previously co-chaired\u0026nbsp;the firm\u0026rsquo;s Life Sciences and Healthcare Industry Group for six years, which is comprised of more than 450\u0026nbsp;lawyers across seventeen practice areas in the firm.\u0026nbsp; In 2024, Nikki was a winner of Corporate Counsel's 2024 Women, Influence \u0026amp; Power in Law Award for Law Firm Thought Leadership.\u0026nbsp; Nikki is ranked nationally by \u003cem\u003eChambers USA\u003c/em\u003e\u0026nbsp;for Life Sciences: Regulatory Compliance and for Pharmaceuticals/Medical Products Regulatory from 2021-2025, named a\u0026nbsp;\u003cem\u003eLMG Life Sciences Star\u003c/em\u003e in FDA Pharmaceutical and in FDA Medical Device from 2019-2025, and was named a\u0026nbsp;\u003cem\u003eLaw360 Compliance MVP\u003c/em\u003e\u0026nbsp;in 2020.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAs Deputy Chair of our FDA \u0026amp; Life Sciences practice, Nikki advises pharmaceutical and medical device companies on pre- and post-market FDA regulatory compliance and enforcement matters ranging from clinical trials, good manufacturing practices, to labeling, advertising, and promotion of FDA-regulated products.\u0026nbsp; Nikki has been the lead FDA regulatory advisor to her clients on 250+ transactional matters.\u0026nbsp; She conducts investigations into FDA clinical trials and post-marking noncompliance, acts as lead compliance and regulatory counsel for several companies under Corporate Integrity Agreements (CIAs) and has led several CMS Open Payments compliance audits.\u0026nbsp; She is an expert on federal Open Payments, state, and international transparency/disclosure laws and leads two pharma and device industry compliance coalitions.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eNikki counsels pharma and device companies on FDA inspections, Form 483s, Warning Letters, product recalls, import detentions, clinical holds, and other FDA compliance and enforcement matters.\u0026nbsp; She conducts risk assessments and internal investigations into allegations of FDA and healthcare program noncompliance.\u0026nbsp; She routinely advises company executives and board members and represents her clients before federal agencies.\u0026nbsp; She has established robust compliance programs and policies for numerous life sciences companies. Nikki has also served as an interim General Counsel and as a Chief Compliance Officer for her life sciences clients.\u003c/p\u003e\n\u003cp\u003eNikki leads two pharma and device industry coalitions on transparency and disclosure laws.\u0026nbsp; The\u0026nbsp;\u003cem\u003eAd Hoc Sunshine and State Law Compliance Group\u003c/em\u003e is a coalition she advises on federal Sunshine Act and state transparency/disclosure and gift ban laws.\u0026nbsp; The \u003cem\u003eInternational Marketing and Disclosure Compliance Group\u003c/em\u003e is a separate coalition of companies she advises on the growing area of transparency and disclosure laws and industry codes of conduct in the EU, Australia, Japan, and numerous other countries and regions.\u003c/p\u003e\n\u003cp\u003eKing \u0026amp; Spalding\u0026rsquo;s FDA \u0026amp; Life Sciences Practice has been named \u003cem\u003eLaw360\u003c/em\u003e Practice Group of the Year from 2017-2020.\u0026nbsp; King \u0026amp; Spalding\u0026rsquo;s FDA \u0026amp; Life Sciences Practice is ranked by Chambers Legal, LMG Life Sciences, U.S. News, and Best Lawyers.\u0026nbsp; According to\u0026nbsp;\u003cem\u003eChambers USA, sources praise Nikki as being \"thoughtful, quick to respond and available.\" -- Chambers USA\u003c/em\u003e\u0026nbsp;(2022)\u003c/p\u003e\n\u003cp\u003eNikki is a frequent speaker and author on FDA advertising/promotion, clinical trials, compliance, and transparency law matters.\u0026nbsp; Nikki was also selected to Law360's 2021 Compliance Editorial Advisory Board\u0026nbsp;and has served\u0026nbsp;on the\u0026nbsp;Advisory Board for FDAnews and the PCF Pharma Congress planning committee.\u0026nbsp; She was formerly on the Food and Drug Law Institute (FDLI) Editorial Advisory Board for the \u003cem\u003eFDLI Food \u0026amp; Drug Law Journal\u003c/em\u003e and a member of the FDLI Medical Device Committee.\u0026nbsp; Nikki has also served on the Leadership Advisory Board for the National Women\u0026rsquo;s Law Center and on the Special Gifts Committee for the Arlington Free Clinic for more than ten\u0026nbsp;years.\u003c/p\u003e\n\u003cp\u003eNikki was elected by her partners in 2017 to serve for three years\u0026nbsp;on the firm\u0026rsquo;s Policy Committee, which is the firm's executive management committee.\u0026nbsp; Nikki served for many years on the firm\u0026rsquo;s Lateral Partner Committee and on the firm's Partners Committee, and was also the Hiring Partner for the Washington, D.C. office.\u003c/p\u003e","slug":"nikki-reeves","email":"nreeves@kslaw.com","phone":null,"matters":["\u003cp\u003eAdvised companies on FDA advertising and promotion rules for drugs, devices, and cosmetics, including social media, new product launches, DTC, physician and payor communications, broadcast ads, reprints, and investor communications.\u003c/p\u003e","\u003cp\u003eAdvised on CMS Open Payments compliance audits and compliance with the federal Physician Payment Sunshine (Open Payments) law, state laws targeting industry marketing practices, sales representation licensing, drug price transparency, and disclosure of clinical trial data. Advised on compliance with global transparency laws and industry codes of conduct.\u003c/p\u003e","\u003cp\u003eAdvised life sciences clients on preparing for FDA inspections of clinical trials sites and manufacturing facilities, and responding to FDA Form 483s, FDA Warning Letters, product recalls, import detentions, and government investigations involving alleged advertising/promotion violations.\u003c/p\u003e","\u003cp\u003eConducted FDA regulatory due diligence and related counseling in connection with more than 200+ transactions involving pharmaceutical, medical device, biotechnology, and cosmetic companies.\u003c/p\u003e","\u003cp\u003eStand up healthcare compliance programs for pharmaceutical and medical device manufacturers and related healthcare compliance policies and codes of conduct. Served as interim Chief Compliance Officer for a pharmaceutical manufacturer for a two year period and managed all aspects of the company healthcare compliance program.\u003c/p\u003e","\u003cp\u003eConducted internal investigations into potential FDA GCP, GMP, and healthcare compliance policy violations.\u003c/p\u003e","\u003cp\u003eLed risk assessments of healthcare regulatory compliance programs and policies and advised on compliance with FDA regulations, HHS OIG Compliance Program Guidance, and the PhRMA and AdvaMed Codes on Interactions with Healthcare Professionals.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":245}]},"expertise":[{"id":81,"guid":"81.capabilities","index":0,"source":"capabilities"},{"id":761,"guid":"761.smart_tags","index":1,"source":"smartTags"},{"id":21,"guid":"21.capabilities","index":2,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":3,"source":"capabilities"},{"id":32,"guid":"32.capabilities","index":4,"source":"capabilities"},{"id":17,"guid":"17.capabilities","index":5,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":6,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":7,"source":"capabilities"},{"id":970,"guid":"970.smart_tags","index":8,"source":"smartTags"},{"id":109,"guid":"109.capabilities","index":9,"source":"capabilities"},{"id":112,"guid":"112.capabilities","index":10,"source":"capabilities"},{"id":114,"guid":"114.capabilities","index":11,"source":"capabilities"},{"id":120,"guid":"120.capabilities","index":12,"source":"capabilities"},{"id":122,"guid":"122.capabilities","index":13,"source":"capabilities"},{"id":1193,"guid":"1193.smart_tags","index":14,"source":"smartTags"},{"id":1223,"guid":"1223.smart_tags","index":15,"source":"smartTags"},{"id":135,"guid":"135.capabilities","index":16,"source":"capabilities"}],"is_active":true,"last_name":"Reeves","nick_name":"Nikki","clerkships":[],"first_name":"Nikki","title_rank":9999,"updated_by":202,"law_schools":[],"middle_name":" ","name_suffix":"","recognitions":[{"title":"Women, Influence \u0026 Power in Law Award for Thought Leadership","detail":"Corporate Counsel 2024"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eNikki Reeves is an FDA and healthcare regulatory compliance lawyer with more than 25\u0026nbsp;years of experience.\u0026nbsp; Nikki co-chairs the firm's Government Matters \u0026amp; Regulatory practice management group, which is comprised of 200+ lawyers and consultants in eight practice areas.\u0026nbsp; Nikki previously co-chaired\u0026nbsp;the firm\u0026rsquo;s Life Sciences and Healthcare Industry Group for six years, which is comprised of more than 450\u0026nbsp;lawyers across seventeen practice areas in the firm.\u0026nbsp; In 2024, Nikki was a winner of Corporate Counsel's 2024 Women, Influence \u0026amp; Power in Law Award for Law Firm Thought Leadership.\u0026nbsp; Nikki is ranked nationally by \u003cem\u003eChambers USA\u003c/em\u003e\u0026nbsp;for Life Sciences: Regulatory Compliance and for Pharmaceuticals/Medical Products Regulatory from 2021-2025, named a\u0026nbsp;\u003cem\u003eLMG Life Sciences Star\u003c/em\u003e in FDA Pharmaceutical and in FDA Medical Device from 2019-2025, and was named a\u0026nbsp;\u003cem\u003eLaw360 Compliance MVP\u003c/em\u003e\u0026nbsp;in 2020.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAs Deputy Chair of our FDA \u0026amp; Life Sciences practice, Nikki advises pharmaceutical and medical device companies on pre- and post-market FDA regulatory compliance and enforcement matters ranging from clinical trials, good manufacturing practices, to labeling, advertising, and promotion of FDA-regulated products.\u0026nbsp; Nikki has been the lead FDA regulatory advisor to her clients on 250+ transactional matters.\u0026nbsp; She conducts investigations into FDA clinical trials and post-marking noncompliance, acts as lead compliance and regulatory counsel for several companies under Corporate Integrity Agreements (CIAs) and has led several CMS Open Payments compliance audits.\u0026nbsp; She is an expert on federal Open Payments, state, and international transparency/disclosure laws and leads two pharma and device industry compliance coalitions.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eNikki counsels pharma and device companies on FDA inspections, Form 483s, Warning Letters, product recalls, import detentions, clinical holds, and other FDA compliance and enforcement matters.\u0026nbsp; She conducts risk assessments and internal investigations into allegations of FDA and healthcare program noncompliance.\u0026nbsp; She routinely advises company executives and board members and represents her clients before federal agencies.\u0026nbsp; She has established robust compliance programs and policies for numerous life sciences companies. Nikki has also served as an interim General Counsel and as a Chief Compliance Officer for her life sciences clients.\u003c/p\u003e\n\u003cp\u003eNikki leads two pharma and device industry coalitions on transparency and disclosure laws.\u0026nbsp; The\u0026nbsp;\u003cem\u003eAd Hoc Sunshine and State Law Compliance Group\u003c/em\u003e is a coalition she advises on federal Sunshine Act and state transparency/disclosure and gift ban laws.\u0026nbsp; The \u003cem\u003eInternational Marketing and Disclosure Compliance Group\u003c/em\u003e is a separate coalition of companies she advises on the growing area of transparency and disclosure laws and industry codes of conduct in the EU, Australia, Japan, and numerous other countries and regions.\u003c/p\u003e\n\u003cp\u003eKing \u0026amp; Spalding\u0026rsquo;s FDA \u0026amp; Life Sciences Practice has been named \u003cem\u003eLaw360\u003c/em\u003e Practice Group of the Year from 2017-2020.\u0026nbsp; King \u0026amp; Spalding\u0026rsquo;s FDA \u0026amp; Life Sciences Practice is ranked by Chambers Legal, LMG Life Sciences, U.S. News, and Best Lawyers.\u0026nbsp; According to\u0026nbsp;\u003cem\u003eChambers USA, sources praise Nikki as being \"thoughtful, quick to respond and available.\" -- Chambers USA\u003c/em\u003e\u0026nbsp;(2022)\u003c/p\u003e\n\u003cp\u003eNikki is a frequent speaker and author on FDA advertising/promotion, clinical trials, compliance, and transparency law matters.\u0026nbsp; Nikki was also selected to Law360's 2021 Compliance Editorial Advisory Board\u0026nbsp;and has served\u0026nbsp;on the\u0026nbsp;Advisory Board for FDAnews and the PCF Pharma Congress planning committee.\u0026nbsp; She was formerly on the Food and Drug Law Institute (FDLI) Editorial Advisory Board for the \u003cem\u003eFDLI Food \u0026amp; Drug Law Journal\u003c/em\u003e and a member of the FDLI Medical Device Committee.\u0026nbsp; Nikki has also served on the Leadership Advisory Board for the National Women\u0026rsquo;s Law Center and on the Special Gifts Committee for the Arlington Free Clinic for more than ten\u0026nbsp;years.\u003c/p\u003e\n\u003cp\u003eNikki was elected by her partners in 2017 to serve for three years\u0026nbsp;on the firm\u0026rsquo;s Policy Committee, which is the firm's executive management committee.\u0026nbsp; Nikki served for many years on the firm\u0026rsquo;s Lateral Partner Committee and on the firm's Partners Committee, and was also the Hiring Partner for the Washington, D.C. office.\u003c/p\u003e","matters":["\u003cp\u003eAdvised companies on FDA advertising and promotion rules for drugs, devices, and cosmetics, including social media, new product launches, DTC, physician and payor communications, broadcast ads, reprints, and investor communications.\u003c/p\u003e","\u003cp\u003eAdvised on CMS Open Payments compliance audits and compliance with the federal Physician Payment Sunshine (Open Payments) law, state laws targeting industry marketing practices, sales representation licensing, drug price transparency, and disclosure of clinical trial data. Advised on compliance with global transparency laws and industry codes of conduct.\u003c/p\u003e","\u003cp\u003eAdvised life sciences clients on preparing for FDA inspections of clinical trials sites and manufacturing facilities, and responding to FDA Form 483s, FDA Warning Letters, product recalls, import detentions, and government investigations involving alleged advertising/promotion violations.\u003c/p\u003e","\u003cp\u003eConducted FDA regulatory due diligence and related counseling in connection with more than 200+ transactions involving pharmaceutical, medical device, biotechnology, and cosmetic companies.\u003c/p\u003e","\u003cp\u003eStand up healthcare compliance programs for pharmaceutical and medical device manufacturers and related healthcare compliance policies and codes of conduct. Served as interim Chief Compliance Officer for a pharmaceutical manufacturer for a two year period and managed all aspects of the company healthcare compliance program.\u003c/p\u003e","\u003cp\u003eConducted internal investigations into potential FDA GCP, GMP, and healthcare compliance policy violations.\u003c/p\u003e","\u003cp\u003eLed risk assessments of healthcare regulatory compliance programs and policies and advised on compliance with FDA regulations, HHS OIG Compliance Program Guidance, and the PhRMA and AdvaMed Codes on Interactions with Healthcare Professionals.\u003c/p\u003e"],"recognitions":[{"title":"Women, Influence \u0026 Power in Law Award for Thought Leadership","detail":"Corporate Counsel 2024"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":1139}]},"capability_group_id":2},"created_at":"2025-07-29T16:08:40.000Z","updated_at":"2025-07-29T16:08:40.000Z","searchable_text":"Reeves{{ FIELD }}{:title=\u0026gt;\"Women, Influence \u0026amp; Power in Law Award for Thought Leadership\", :detail=\u0026gt;\"Corporate Counsel 2024\"}{{ FIELD }}Advised companies on FDA advertising and promotion rules for drugs, devices, and cosmetics, including social media, new product launches, DTC, physician and payor communications, broadcast ads, reprints, and investor communications.{{ FIELD }}Advised on CMS Open Payments compliance audits and compliance with the federal Physician Payment Sunshine (Open Payments) law, state laws targeting industry marketing practices, sales representation licensing, drug price transparency, and disclosure of clinical trial data. Advised on compliance with global transparency laws and industry codes of conduct.{{ FIELD }}Advised life sciences clients on preparing for FDA inspections of clinical trials sites and manufacturing facilities, and responding to FDA Form 483s, FDA Warning Letters, product recalls, import detentions, and government investigations involving alleged advertising/promotion violations.{{ FIELD }}Conducted FDA regulatory due diligence and related counseling in connection with more than 200+ transactions involving pharmaceutical, medical device, biotechnology, and cosmetic companies.{{ FIELD }}Stand up healthcare compliance programs for pharmaceutical and medical device manufacturers and related healthcare compliance policies and codes of conduct. Served as interim Chief Compliance Officer for a pharmaceutical manufacturer for a two year period and managed all aspects of the company healthcare compliance program.{{ FIELD }}Conducted internal investigations into potential FDA GCP, GMP, and healthcare compliance policy violations.{{ FIELD }}Led risk assessments of healthcare regulatory compliance programs and policies and advised on compliance with FDA regulations, HHS OIG Compliance Program Guidance, and the PhRMA and AdvaMed Codes on Interactions with Healthcare Professionals.{{ FIELD }}Nikki Reeves is an FDA and healthcare regulatory compliance lawyer with more than 25 years of experience.  Nikki co-chairs the firm's Government Matters \u0026amp; Regulatory practice management group, which is comprised of 200+ lawyers and consultants in eight practice areas.  Nikki previously co-chaired the firm’s Life Sciences and Healthcare Industry Group for six years, which is comprised of more than 450 lawyers across seventeen practice areas in the firm.  In 2024, Nikki was a winner of Corporate Counsel's 2024 Women, Influence \u0026amp; Power in Law Award for Law Firm Thought Leadership.  Nikki is ranked nationally by Chambers USA for Life Sciences: Regulatory Compliance and for Pharmaceuticals/Medical Products Regulatory from 2021-2025, named a LMG Life Sciences Star in FDA Pharmaceutical and in FDA Medical Device from 2019-2025, and was named a Law360 Compliance MVP in 2020. \nAs Deputy Chair of our FDA \u0026amp; Life Sciences practice, Nikki advises pharmaceutical and medical device companies on pre- and post-market FDA regulatory compliance and enforcement matters ranging from clinical trials, good manufacturing practices, to labeling, advertising, and promotion of FDA-regulated products.  Nikki has been the lead FDA regulatory advisor to her clients on 250+ transactional matters.  She conducts investigations into FDA clinical trials and post-marking noncompliance, acts as lead compliance and regulatory counsel for several companies under Corporate Integrity Agreements (CIAs) and has led several CMS Open Payments compliance audits.  She is an expert on federal Open Payments, state, and international transparency/disclosure laws and leads two pharma and device industry compliance coalitions. \nNikki counsels pharma and device companies on FDA inspections, Form 483s, Warning Letters, product recalls, import detentions, clinical holds, and other FDA compliance and enforcement matters.  She conducts risk assessments and internal investigations into allegations of FDA and healthcare program noncompliance.  She routinely advises company executives and board members and represents her clients before federal agencies.  She has established robust compliance programs and policies for numerous life sciences companies. Nikki has also served as an interim General Counsel and as a Chief Compliance Officer for her life sciences clients.\nNikki leads two pharma and device industry coalitions on transparency and disclosure laws.  The Ad Hoc Sunshine and State Law Compliance Group is a coalition she advises on federal Sunshine Act and state transparency/disclosure and gift ban laws.  The International Marketing and Disclosure Compliance Group is a separate coalition of companies she advises on the growing area of transparency and disclosure laws and industry codes of conduct in the EU, Australia, Japan, and numerous other countries and regions.\nKing \u0026amp; Spalding’s FDA \u0026amp; Life Sciences Practice has been named Law360 Practice Group of the Year from 2017-2020.  King \u0026amp; Spalding’s FDA \u0026amp; Life Sciences Practice is ranked by Chambers Legal, LMG Life Sciences, U.S. News, and Best Lawyers.  According to Chambers USA, sources praise Nikki as being \"thoughtful, quick to respond and available.\" -- Chambers USA (2022)\nNikki is a frequent speaker and author on FDA advertising/promotion, clinical trials, compliance, and transparency law matters.  Nikki was also selected to Law360's 2021 Compliance Editorial Advisory Board and has served on the Advisory Board for FDAnews and the PCF Pharma Congress planning committee.  She was formerly on the Food and Drug Law Institute (FDLI) Editorial Advisory Board for the FDLI Food \u0026amp; Drug Law Journal and a member of the FDLI Medical Device Committee.  Nikki has also served on the Leadership Advisory Board for the National Women’s Law Center and on the Special Gifts Committee for the Arlington Free Clinic for more than ten years.\nNikki was elected by her partners in 2017 to serve for three years on the firm’s Policy Committee, which is the firm's executive management committee.  Nikki served for many years on the firm’s Lateral Partner Committee and on the firm's Partners Committee, and was also the Hiring Partner for the Washington, D.C. office. Kelly Reeves Partner Women, Influence \u0026amp; Power in Law Award for Thought Leadership Corporate Counsel 2024 North Carolina State University  University of Maryland  North Carolina State University  District of Columbia Maryland Advised companies on FDA advertising and promotion rules for drugs, devices, and cosmetics, including social media, new product launches, DTC, physician and payor communications, broadcast ads, reprints, and investor communications. Advised on CMS Open Payments compliance audits and compliance with the federal Physician Payment Sunshine (Open Payments) law, state laws targeting industry marketing practices, sales representation licensing, drug price transparency, and disclosure of clinical trial data. Advised on compliance with global transparency laws and industry codes of conduct. Advised life sciences clients on preparing for FDA inspections of clinical trials sites and manufacturing facilities, and responding to FDA Form 483s, FDA Warning Letters, product recalls, import detentions, and government investigations involving alleged advertising/promotion violations. Conducted FDA regulatory due diligence and related counseling in connection with more than 200+ transactions involving pharmaceutical, medical device, biotechnology, and cosmetic companies. Stand up healthcare compliance programs for pharmaceutical and medical device manufacturers and related healthcare compliance policies and codes of conduct. Served as interim Chief Compliance Officer for a pharmaceutical manufacturer for a two year period and managed all aspects of the company healthcare compliance program. Conducted internal investigations into potential FDA GCP, GMP, and healthcare compliance policy violations. Led risk assessments of healthcare regulatory compliance programs and policies and advised on compliance with FDA regulations, HHS OIG Compliance Program Guidance, and the PhRMA and AdvaMed Codes on Interactions with Healthcare Professionals.","searchable_name":"Nikki Reeves","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":436367,"version":1,"owner_type":"Person","owner_id":2254,"payload":{"bio":"\u003cp\u003eKim Roeder focuses on the healthcare sector, particularly with regard to compliance, investigations and transactions. As a partner in our Healthcare practice, Kim represents individual and institutional healthcare providers, along with suppliers, in a wide range of matters.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eKim advises healthcare suppliers and providers, including hospital systems, academic medical centers and physician practice groups, on implementing compliance programs as well as conducting compliance assessments and internal investigations. She frequently represents healthcare providers in responding to Department of Justice and Office of Inspector General investigations and\u0026nbsp;\u003cem\u003equi tam\u003c/em\u003e\u0026nbsp;actions, and in voluntary disclosures through agency programs.\u003c/p\u003e\n\u003cp\u003eIn addition, Kim has extensive experience advising clients on Medicare and Medicaid reimbursement issues; federal and state self-referral and anti-kickback laws; delivery system reform; accountable care organizations; shared savings and incentive payment arrangements; clinically integrated networks; and hospital-physician employment relationships and other affiliations.\u003c/p\u003e\n\u003cp\u003eKim is an Adjunct Professor at the Georgia State University College of Law. A frequent author and speaker before professional and trade groups, Kim is a member of the American Health Lawyers Association and the Health Care Compliance Association, and a former president of the Georgia Academy of Healthcare Attorneys.\u003c/p\u003e\n\u003cp\u003eKim holds a top ranking among Georgia healthcare lawyers in\u0026nbsp;\u003cem\u003eChambers USA,\u003c/em\u003e\u0026nbsp;and has been recognized for more than 10 years as one of\u0026nbsp;\u003cem\u003eThe\u003c/em\u003e\u0026nbsp;\u003cem\u003eBest Lawyers in America\u003c/em\u003e\u0026nbsp;for Healthcare Law. In addition, she has been selected as a Georgia Super Lawyer by\u0026nbsp;\u003cem\u003eSuper Lawyers\u003c/em\u003e\u0026nbsp;since 2004, and named an Outstanding Healthcare Fraud and Compliance Lawyer in\u0026nbsp;\u003cem\u003eNightingale\u0026rsquo;s Healthcare News.\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublications\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026ldquo;The Stark Law and Regulations,\u0026rdquo;\u0026nbsp;\u003cem\u003eCompliance Manual\u003c/em\u003e, Healthcare Compliance Association (2009, 2011 and 2016 updates)\u003c/li\u003e\n\u003cli\u003eAmerican Health Lawyers Association, Business Law and Governance Practice Group,\u0026nbsp;\u003cem\u003eExecutive Summary\u003c/em\u003e\u0026nbsp;(December 2009), \u0026ldquo;The New Healthcare Delivery System:\u0026nbsp; What are Accountable Care Organizations and Medical Homes?\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eAmerican Health Lawyers Association, Business Law and Governance Practice Group, Business Law Update (September 9, 2009), \u0026ldquo;Healthcare Reform Will Challenge Providers\u0026rsquo; Business Structures\u0026rdquo;\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003cstrong\u003eSpeaking Engagements\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eAmerican Health Lawyers Association, Physicians and Hospitals Law Institute, February 10-12, 2020, \u0026ldquo;The Regulatory Sprint to Coordinated Care:\u0026nbsp; Are We There Yet?\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eKing \u0026amp; Spalding Roundtable Webinars, November 7, 2019 and November 20, 2019: Recalculating:\u0026nbsp; Are the Major Stark, Anti-Kickback and CMP Proposed Rule Changes Taking Us in a New Direction?\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eABA Health Law Section Webinar, \u0026ldquo;Head Start:\u0026nbsp; What You Need to Know Now About the Newly Proposed AKS Regulations,\u0026rdquo; November 5, 2019.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e26th Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2017: \u0026nbsp;Participation in Panel Presentation, \u0026ldquo;Fulfilling Campaign Promises:\u0026nbsp; ACA Repeal and Replace\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAICPA Health Care Industry Conference, November 2016:\u0026nbsp; \u0026ldquo;ACA Update: Where are We and What\u0026rsquo;s Coming?\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eKing \u0026amp; Spalding Roundtable Program, December 2014:\u0026nbsp; \u0026ldquo;The New \u0026lsquo;Selfie\u0026rsquo;: Self Disclosures and Voluntary Repayments under Medicare\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e22nd Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2013:\u0026nbsp; Panel Presentation \u0026ndash; \u0026ldquo;Healthcare Reform Countdown\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003eArkansas Hospital Association, August 2012:\u0026nbsp; \u0026ldquo;Update on Delivery System and Payment Reforms\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eKing \u0026amp; Spalding Roundtable Program, August 2012:\u0026nbsp; \u0026ldquo;Recent Medicaid Developments from the Implementation of the Supreme Court\u0026rsquo;s Ruling on PPACA, Enforcement Activities and Other Medicaid Reforms\u0026rdquo;\u003c/li\u003e\n\u003cli\u003e21st Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2012:\u0026nbsp; Panel Presentation, \u0026ldquo;Delivery System Evolution:\u0026nbsp; Competing on Cost and Quality\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eHCCA Southeast Regional Annual Conference, January 2012:\u0026nbsp; \u0026ldquo;Compliance Issues in Accountable Care: Shared Savings, Bundled Payments and other Innovations\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eGeorgia State University College of Law and Center for Law, Health and Society, January 2012:\u0026nbsp; \u0026ldquo;Update -- The Progress of Healthcare Delivery System Reform\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eKing \u0026amp; Spalding Roundtable Program, November 2011:\u0026nbsp; \u0026ldquo;Qualifying as an Accountable Care Organization in the CMS Shared Savings Program:\u0026nbsp; Overview of the Final Rule and Agency Announcements\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eTennessee Hospital Association Fall Compliance Conference, October 2011:\u0026nbsp; \u0026ldquo;Compliance Issues in Accountable Care Organizations and Innovative Payment Arrangements\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eGeorgia Bio/Georgia Association of Healthcare Executives, October 2011:\u0026nbsp; \u0026ldquo;Technology That Will Create Accountable Care:\u0026nbsp; Legal Framework for Accountable Care Organizations and Innovative Payment Arrangements\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eGeorgia Healthcare Financial Management Association, July 2011:\u0026nbsp; Accountable Care Organizations\u003c/li\u003e\n\u003cli\u003eKing \u0026amp; Spalding Roundtable Program, April 2011:\u0026nbsp; \u0026ldquo;Planning to Qualify as an Accountable Care Organization:\u0026nbsp; Proposed Rule and Agency Notices\u0026rdquo;\u003c/li\u003e\n\u003c/ul\u003e\n\u003cul\u003e\n\u003cli\u003eEast Tennessee Healthcare Fraud Working Group, April 2011:\u0026nbsp; \u0026ldquo;Health Care Reform and Compliance Issues\u0026rdquo;\u003c/li\u003e\n\u003cli\u003e20th Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2011:\u0026nbsp; \u0026ldquo;Legal and Regulatory Conflicts in PPACA\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eAmerican Health Lawyers Association, June 2010:\u0026nbsp; \u0026ldquo;Quality-Based Compensation in a New Era of Health Reform\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eGeorgia Academy of Healthcare Attorneys, May 2010:\u0026nbsp; \u0026ldquo;Hospital-Physician Alignment\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eKing \u0026amp; Spalding Roundtable Program, May 2010:\u0026nbsp; \u0026ldquo;Reform Driven Strategies and Tactics\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eAmerican Health Lawyers Association, Moderator of national teleconference, April 2010, regarding Care Coordination Models\u003c/li\u003e\n\u003cli\u003eKing \u0026amp; Spalding Roundtable Program, April 2010:\u0026nbsp; \u0026ldquo;Healthcare Reform Legislation -- Medicare, Medicaid and Delivery System Reform\u0026rdquo;\u003c/li\u003e\n\u003c/ul\u003e","slug":"kim-roeder","email":"kroeder@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[{"id":97}]},"expertise":[{"id":23,"guid":"23.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":2,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":3,"source":"capabilities"},{"id":826,"guid":"826.smart_tags","index":4,"source":"smartTags"}],"is_active":true,"last_name":"Roeder","nick_name":"Kim","clerkships":[],"first_name":"Kim","title_rank":9999,"updated_by":174,"law_schools":[],"middle_name":"H.","name_suffix":"","recognitions":[{"title":"Top ranking among Georgia healthcare lawyers ","detail":"Chambers USA"},{"title":"Healthcare Law ","detail":"The Best Lawyers in America, 10+ years"},{"title":"Georgia Super Lawyer ","detail":"Super Lawyers"},{"title":"Outstanding Healthcare Fraud and Compliance Lawyer ","detail":"Nightingale’s Healthcare News"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eKim Roeder focuses on the healthcare sector, particularly with regard to compliance, investigations and transactions. As a partner in our Healthcare practice, Kim represents individual and institutional healthcare providers, along with suppliers, in a wide range of matters.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eKim advises healthcare suppliers and providers, including hospital systems, academic medical centers and physician practice groups, on implementing compliance programs as well as conducting compliance assessments and internal investigations. She frequently represents healthcare providers in responding to Department of Justice and Office of Inspector General investigations and\u0026nbsp;\u003cem\u003equi tam\u003c/em\u003e\u0026nbsp;actions, and in voluntary disclosures through agency programs.\u003c/p\u003e\n\u003cp\u003eIn addition, Kim has extensive experience advising clients on Medicare and Medicaid reimbursement issues; federal and state self-referral and anti-kickback laws; delivery system reform; accountable care organizations; shared savings and incentive payment arrangements; clinically integrated networks; and hospital-physician employment relationships and other affiliations.\u003c/p\u003e\n\u003cp\u003eKim is an Adjunct Professor at the Georgia State University College of Law. A frequent author and speaker before professional and trade groups, Kim is a member of the American Health Lawyers Association and the Health Care Compliance Association, and a former president of the Georgia Academy of Healthcare Attorneys.\u003c/p\u003e\n\u003cp\u003eKim holds a top ranking among Georgia healthcare lawyers in\u0026nbsp;\u003cem\u003eChambers USA,\u003c/em\u003e\u0026nbsp;and has been recognized for more than 10 years as one of\u0026nbsp;\u003cem\u003eThe\u003c/em\u003e\u0026nbsp;\u003cem\u003eBest Lawyers in America\u003c/em\u003e\u0026nbsp;for Healthcare Law. In addition, she has been selected as a Georgia Super Lawyer by\u0026nbsp;\u003cem\u003eSuper Lawyers\u003c/em\u003e\u0026nbsp;since 2004, and named an Outstanding Healthcare Fraud and Compliance Lawyer in\u0026nbsp;\u003cem\u003eNightingale\u0026rsquo;s Healthcare News.\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublications\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026ldquo;The Stark Law and Regulations,\u0026rdquo;\u0026nbsp;\u003cem\u003eCompliance Manual\u003c/em\u003e, Healthcare Compliance Association (2009, 2011 and 2016 updates)\u003c/li\u003e\n\u003cli\u003eAmerican Health Lawyers Association, Business Law and Governance Practice Group,\u0026nbsp;\u003cem\u003eExecutive Summary\u003c/em\u003e\u0026nbsp;(December 2009), \u0026ldquo;The New Healthcare Delivery System:\u0026nbsp; What are Accountable Care Organizations and Medical Homes?\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eAmerican Health Lawyers Association, Business Law and Governance Practice Group, Business Law Update (September 9, 2009), \u0026ldquo;Healthcare Reform Will Challenge Providers\u0026rsquo; Business Structures\u0026rdquo;\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003cstrong\u003eSpeaking Engagements\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eAmerican Health Lawyers Association, Physicians and Hospitals Law Institute, February 10-12, 2020, \u0026ldquo;The Regulatory Sprint to Coordinated Care:\u0026nbsp; Are We There Yet?\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eKing \u0026amp; Spalding Roundtable Webinars, November 7, 2019 and November 20, 2019: Recalculating:\u0026nbsp; Are the Major Stark, Anti-Kickback and CMP Proposed Rule Changes Taking Us in a New Direction?\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eABA Health Law Section Webinar, \u0026ldquo;Head Start:\u0026nbsp; What You Need to Know Now About the Newly Proposed AKS Regulations,\u0026rdquo; November 5, 2019.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e26th Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2017: \u0026nbsp;Participation in Panel Presentation, \u0026ldquo;Fulfilling Campaign Promises:\u0026nbsp; ACA Repeal and Replace\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAICPA Health Care Industry Conference, November 2016:\u0026nbsp; \u0026ldquo;ACA Update: Where are We and What\u0026rsquo;s Coming?\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eKing \u0026amp; Spalding Roundtable Program, December 2014:\u0026nbsp; \u0026ldquo;The New \u0026lsquo;Selfie\u0026rsquo;: Self Disclosures and Voluntary Repayments under Medicare\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e22nd Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2013:\u0026nbsp; Panel Presentation \u0026ndash; \u0026ldquo;Healthcare Reform Countdown\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003eArkansas Hospital Association, August 2012:\u0026nbsp; \u0026ldquo;Update on Delivery System and Payment Reforms\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eKing \u0026amp; Spalding Roundtable Program, August 2012:\u0026nbsp; \u0026ldquo;Recent Medicaid Developments from the Implementation of the Supreme Court\u0026rsquo;s Ruling on PPACA, Enforcement Activities and Other Medicaid Reforms\u0026rdquo;\u003c/li\u003e\n\u003cli\u003e21st Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2012:\u0026nbsp; Panel Presentation, \u0026ldquo;Delivery System Evolution:\u0026nbsp; Competing on Cost and Quality\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eHCCA Southeast Regional Annual Conference, January 2012:\u0026nbsp; \u0026ldquo;Compliance Issues in Accountable Care: Shared Savings, Bundled Payments and other Innovations\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eGeorgia State University College of Law and Center for Law, Health and Society, January 2012:\u0026nbsp; \u0026ldquo;Update -- The Progress of Healthcare Delivery System Reform\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eKing \u0026amp; Spalding Roundtable Program, November 2011:\u0026nbsp; \u0026ldquo;Qualifying as an Accountable Care Organization in the CMS Shared Savings Program:\u0026nbsp; Overview of the Final Rule and Agency Announcements\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eTennessee Hospital Association Fall Compliance Conference, October 2011:\u0026nbsp; \u0026ldquo;Compliance Issues in Accountable Care Organizations and Innovative Payment Arrangements\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eGeorgia Bio/Georgia Association of Healthcare Executives, October 2011:\u0026nbsp; \u0026ldquo;Technology That Will Create Accountable Care:\u0026nbsp; Legal Framework for Accountable Care Organizations and Innovative Payment Arrangements\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eGeorgia Healthcare Financial Management Association, July 2011:\u0026nbsp; Accountable Care Organizations\u003c/li\u003e\n\u003cli\u003eKing \u0026amp; Spalding Roundtable Program, April 2011:\u0026nbsp; \u0026ldquo;Planning to Qualify as an Accountable Care Organization:\u0026nbsp; Proposed Rule and Agency Notices\u0026rdquo;\u003c/li\u003e\n\u003c/ul\u003e\n\u003cul\u003e\n\u003cli\u003eEast Tennessee Healthcare Fraud Working Group, April 2011:\u0026nbsp; \u0026ldquo;Health Care Reform and Compliance Issues\u0026rdquo;\u003c/li\u003e\n\u003cli\u003e20th Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2011:\u0026nbsp; \u0026ldquo;Legal and Regulatory Conflicts in PPACA\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eAmerican Health Lawyers Association, June 2010:\u0026nbsp; \u0026ldquo;Quality-Based Compensation in a New Era of Health Reform\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eGeorgia Academy of Healthcare Attorneys, May 2010:\u0026nbsp; \u0026ldquo;Hospital-Physician Alignment\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eKing \u0026amp; Spalding Roundtable Program, May 2010:\u0026nbsp; \u0026ldquo;Reform Driven Strategies and Tactics\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eAmerican Health Lawyers Association, Moderator of national teleconference, April 2010, regarding Care Coordination Models\u003c/li\u003e\n\u003cli\u003eKing \u0026amp; Spalding Roundtable Program, April 2010:\u0026nbsp; \u0026ldquo;Healthcare Reform Legislation -- Medicare, Medicaid and Delivery System Reform\u0026rdquo;\u003c/li\u003e\n\u003c/ul\u003e","recognitions":[{"title":"Top ranking among Georgia healthcare lawyers ","detail":"Chambers USA"},{"title":"Healthcare Law ","detail":"The Best Lawyers in America, 10+ years"},{"title":"Georgia Super Lawyer ","detail":"Super Lawyers"},{"title":"Outstanding Healthcare Fraud and Compliance Lawyer ","detail":"Nightingale’s Healthcare News"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":11804}]},"capability_group_id":2},"created_at":"2025-09-02T04:50:41.000Z","updated_at":"2025-09-02T04:50:41.000Z","searchable_text":"Roeder{{ FIELD }}{:title=\u0026gt;\"Top ranking among Georgia healthcare lawyers \", :detail=\u0026gt;\"Chambers USA\"}{{ FIELD }}{:title=\u0026gt;\"Healthcare Law \", :detail=\u0026gt;\"The Best Lawyers in America, 10+ years\"}{{ FIELD }}{:title=\u0026gt;\"Georgia Super Lawyer \", :detail=\u0026gt;\"Super Lawyers\"}{{ FIELD }}{:title=\u0026gt;\"Outstanding Healthcare Fraud and Compliance Lawyer \", :detail=\u0026gt;\"Nightingale’s Healthcare News\"}{{ FIELD }}Kim Roeder focuses on the healthcare sector, particularly with regard to compliance, investigations and transactions. As a partner in our Healthcare practice, Kim represents individual and institutional healthcare providers, along with suppliers, in a wide range of matters.\nKim advises healthcare suppliers and providers, including hospital systems, academic medical centers and physician practice groups, on implementing compliance programs as well as conducting compliance assessments and internal investigations. She frequently represents healthcare providers in responding to Department of Justice and Office of Inspector General investigations and qui tam actions, and in voluntary disclosures through agency programs.\nIn addition, Kim has extensive experience advising clients on Medicare and Medicaid reimbursement issues; federal and state self-referral and anti-kickback laws; delivery system reform; accountable care organizations; shared savings and incentive payment arrangements; clinically integrated networks; and hospital-physician employment relationships and other affiliations.\nKim is an Adjunct Professor at the Georgia State University College of Law. A frequent author and speaker before professional and trade groups, Kim is a member of the American Health Lawyers Association and the Health Care Compliance Association, and a former president of the Georgia Academy of Healthcare Attorneys.\nKim holds a top ranking among Georgia healthcare lawyers in Chambers USA, and has been recognized for more than 10 years as one of The Best Lawyers in America for Healthcare Law. In addition, she has been selected as a Georgia Super Lawyer by Super Lawyers since 2004, and named an Outstanding Healthcare Fraud and Compliance Lawyer in Nightingale’s Healthcare News.\nPublications\n\n“The Stark Law and Regulations,” Compliance Manual, Healthcare Compliance Association (2009, 2011 and 2016 updates)\nAmerican Health Lawyers Association, Business Law and Governance Practice Group, Executive Summary (December 2009), “The New Healthcare Delivery System:  What are Accountable Care Organizations and Medical Homes?”\nAmerican Health Lawyers Association, Business Law and Governance Practice Group, Business Law Update (September 9, 2009), “Healthcare Reform Will Challenge Providers’ Business Structures”\n\nSpeaking Engagements\n\n\nAmerican Health Lawyers Association, Physicians and Hospitals Law Institute, February 10-12, 2020, “The Regulatory Sprint to Coordinated Care:  Are We There Yet?”\n\n\nKing \u0026amp; Spalding Roundtable Webinars, November 7, 2019 and November 20, 2019: Recalculating:  Are the Major Stark, Anti-Kickback and CMP Proposed Rule Changes Taking Us in a New Direction?\n\n\nABA Health Law Section Webinar, “Head Start:  What You Need to Know Now About the Newly Proposed AKS Regulations,” November 5, 2019.\n\n\n26th Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2017:  Participation in Panel Presentation, “Fulfilling Campaign Promises:  ACA Repeal and Replace”\n\n\nAICPA Health Care Industry Conference, November 2016:  “ACA Update: Where are We and What’s Coming?”\n\n\nKing \u0026amp; Spalding Roundtable Program, December 2014:  “The New ‘Selfie’: Self Disclosures and Voluntary Repayments under Medicare”\n\n\n22nd Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2013:  Panel Presentation – “Healthcare Reform Countdown”\n\nArkansas Hospital Association, August 2012:  “Update on Delivery System and Payment Reforms”\nKing \u0026amp; Spalding Roundtable Program, August 2012:  “Recent Medicaid Developments from the Implementation of the Supreme Court’s Ruling on PPACA, Enforcement Activities and Other Medicaid Reforms”\n21st Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2012:  Panel Presentation, “Delivery System Evolution:  Competing on Cost and Quality”\nHCCA Southeast Regional Annual Conference, January 2012:  “Compliance Issues in Accountable Care: Shared Savings, Bundled Payments and other Innovations”\nGeorgia State University College of Law and Center for Law, Health and Society, January 2012:  “Update -- The Progress of Healthcare Delivery System Reform”\nKing \u0026amp; Spalding Roundtable Program, November 2011:  “Qualifying as an Accountable Care Organization in the CMS Shared Savings Program:  Overview of the Final Rule and Agency Announcements”\nTennessee Hospital Association Fall Compliance Conference, October 2011:  “Compliance Issues in Accountable Care Organizations and Innovative Payment Arrangements”\nGeorgia Bio/Georgia Association of Healthcare Executives, October 2011:  “Technology That Will Create Accountable Care:  Legal Framework for Accountable Care Organizations and Innovative Payment Arrangements”\nGeorgia Healthcare Financial Management Association, July 2011:  Accountable Care Organizations\nKing \u0026amp; Spalding Roundtable Program, April 2011:  “Planning to Qualify as an Accountable Care Organization:  Proposed Rule and Agency Notices”\n\n\nEast Tennessee Healthcare Fraud Working Group, April 2011:  “Health Care Reform and Compliance Issues”\n20th Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2011:  “Legal and Regulatory Conflicts in PPACA”\nAmerican Health Lawyers Association, June 2010:  “Quality-Based Compensation in a New Era of Health Reform”\nGeorgia Academy of Healthcare Attorneys, May 2010:  “Hospital-Physician Alignment”\nKing \u0026amp; Spalding Roundtable Program, May 2010:  “Reform Driven Strategies and Tactics”\nAmerican Health Lawyers Association, Moderator of national teleconference, April 2010, regarding Care Coordination Models\nKing \u0026amp; Spalding Roundtable Program, April 2010:  “Healthcare Reform Legislation -- Medicare, Medicaid and Delivery System Reform”\n Kim H Roeder Partner Top ranking among Georgia healthcare lawyers  Chambers USA Healthcare Law  The Best Lawyers in America, 10+ years Georgia Super Lawyer  Super Lawyers Outstanding Healthcare Fraud and Compliance Lawyer  Nightingale’s Healthcare News Cornell University Cornell Law School Case Western Reserve University Case Western Reserve University School of Law Georgia Health Care Compliance Association Georgia Academy of Healthcare Attorneys, Past President and Board Member American Bar Association, Health Law Section, Business and Corporate Section State Bar of Georgia, Health Law Section, Corporate Law Section Adjunct Professor, Georgia State University College of Law American Health Lawyers Association, Former Co-Chair of the Transactions Affinity Group of the Business Law and Governance Practice Group","searchable_name":"Kim H. Roeder","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":174,"capability_group_featured":null,"home_page_featured":null},{"id":435809,"version":1,"owner_type":"Person","owner_id":6591,"payload":{"bio":"\u003cp\u003eSean Royall serves as the firm\u0026rsquo;s Global Practice Head for Antitrust and Consumer Protection. He has spent his entire career handling complex litigation matters and government investigations and is among the country\u0026rsquo;s most experienced and highly regarded antitrust lawyers. He focuses broadly on antitrust and consumer protection litigation, government investigations, and counseling, and is a highly experienced courtroom litigator with a stellar track record for winning high-stakes cases. Sean is equally effective navigating complex government investigations and advising clients on the details of a wide range of strategic antitrust and consumer protection issues.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eSean previously served at the Federal Trade Commission (FTC) as the Deputy Director of the FTC\u0026rsquo;s Bureau of Competition. His antitrust career, both in government and private practice, has included work on many major mergers and acquisitions, as well as lead roles in complex litigation matters that often intersect with other areas of law, including patent law, various federal regulatory regimes, consumer protection, and privacy. Sean has deep experience representing clients across a range of industries, including biopharma, healthcare, e-commerce, telecom, financial services, energy, transportation, software, and semiconductors. In addition\u0026nbsp;to his work on U.S. antitrust and consumer protection matters, Sean has worked and advised on many similar cases and investigations in Europe and other parts of the world.\u003c/p\u003e\n\u003cp\u003eWhile\u0026nbsp;in government, Sean\u0026nbsp;was the lead trial lawyer in the FTC\u0026rsquo;s landmark monopolization suit against computer chip maker Rambus Inc., a novel case that established new legal standards applicable to patent disclosure within industry standard-setting consortiums. More recently, Sean played an important role on the trial team for AT\u0026amp;T in the company\u0026rsquo;s victory over the Department of Justice\u0026rsquo;s antitrust challenge to AT\u0026amp;T\u0026rsquo;s US$85 billion acquisition of Time Warner. In addition to his trial experience, Sean has successfully argued appeals in courts around the country.\u003c/p\u003e\n\u003cp\u003eSean also has a nationally prominent reputation for his work in the consumer protection area, where he has particularly deep experience handling FTC investigations and associated litigation focused on advertising, marketing, privacy, and data security issues. In 2018-19, for example, Sean served as lead counsel for Facebook in connection with the FTC\u0026rsquo;s extensive privacy-related investigation and subsequent settlement. He brings to this area of his practice deep knowledge of applicable law and agency practice, as well as the skills of an accomplished litigator.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eFor well more than a decade, Sean has been given a Band 1 ranking by\u0026nbsp;\u003cem\u003eChambers USA\u0026nbsp;\u003c/em\u003e(2007-2025)\u003cem\u003e,\u0026nbsp;\u003c/em\u003ewhich has described him as \u0026ldquo;top of the field,\u0026rdquo; \u0026ldquo;a star in the antitrust world both in counseling and litigation,\u0026rdquo; and an \u0026ldquo;extremely talented lawyer and exceptional litigator.\u0026rdquo;\u003c/p\u003e\n\u003cp\u003eSean\u0026rsquo;s other recognitions include being ranked in\u0026nbsp;\u003cem\u003eChambers Global\u003c/em\u003e\u0026nbsp;for Antitrust \u0026ndash; USA (2020-2023); endorsed as \u0026ldquo;Highly Recommended (Texas)\u0026rdquo; by\u0026nbsp;\u003cem\u003eGlobal Competition Review\u003c/em\u003e\u0026nbsp;(2025); named a \u0026ldquo;Litigation Star\u0026rdquo; for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work by\u0026nbsp;\u003cem\u003eBenchmark Litigation\u003c/em\u003e\u0026nbsp;(2023). He is named by \u003cem\u003eLexology\u003c/em\u003e as a \"Competition Thought Leader\" (2025);\u0026nbsp;\u003cem\u003e\u0026nbsp;The Best Lawyers in America\u003c/em\u003e\u0026nbsp;as \u0026ldquo;Antitrust Lawyer of the Year\u0026rdquo; (2015, 2018); and \u003cem\u003eThe Best Lawyers in America\u003c/em\u003e\u0026nbsp;as \u0026ldquo;Litigation: Antitrust Lawyer of the Year\u0026rdquo; (2019). He has also been named to the \u0026ldquo;All-Star List\u0026rdquo; by BTI Services (2017) and deemed a \u0026ldquo;National Antitrust MVP\u0026rdquo; by\u0026nbsp;\u003cem\u003eLaw360\u003c/em\u003e\u0026nbsp;(2015); a \u0026ldquo;Mergers and Acquisitions and Antitrust Trailblazer\u0026rdquo; by\u0026nbsp;\u003cem\u003eNational Law Journal\u003c/em\u003e\u0026nbsp;(2015); and a \u0026ldquo;Life Sciences Star\u0026rdquo; in Antitrust (2022) and Competition and Antitrust (2018\u0026ndash;2019) by\u0026nbsp;\u003cem\u003eLMG Life Sciences\u003c/em\u003e. For the fourth year in a row, Sean was also named by \u003cem\u003eLawdragon \u003c/em\u003eas one of the \"500 Leading Litigators in America.\"\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublications\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSean has written extensively on a wide range of topics relevant to, among other things, antitrust law and policy, consumer protection, privacy, FTC process and remedies, class action antitrust litigation, pharmaceutical antitrust, and standard setting. Sean previously served as Editorial Chair of the ABA\u0026rsquo;s\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, and as an editor of the ABA\u0026rsquo;s\u0026nbsp;\u003cem\u003eAntitrust\u003c/em\u003e\u0026nbsp;magazine and of the Von Kalinowski treatise on\u0026nbsp;\u003cem\u003eAntitrust Laws and Trade Regulation\u003c/em\u003e.\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eAuthor, \u0026ldquo;A Google Breakup Would Serve Progressive Aims and Punish Business,\u0026rdquo; \u003cem\u003eBloomberg Law\u003c/em\u003e, October 5, 2023.\u003c/li\u003e\n\u003cli\u003eAuthor, \u0026ldquo;The FTC\u0026rsquo;s Punctuated Equilibrium,\u0026rdquo; \u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, September 2023.\u003c/li\u003e\n\u003cli\u003eAuthor, \u0026ldquo;The FTC\u0026rsquo;s COPPA Conundrum: Ambiguities in the Rule and a Dearth of Authoritative Guidance Leave the Agency Vulnerable to Legal Challenges\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, September 9, 2022.\u003c/li\u003e\n\u003cli\u003eAuthor, \u0026ldquo;Antitrust and Consumer Protection at Last Converge,\u0026rdquo;\u0026nbsp;\u003cem\u003eCorporate Counsel\u003c/em\u003e, April 27, 2022.\u003c/li\u003e\n\u003cli\u003eQuoted in, \u0026ldquo;CFPB May Fill Enforcement Gap After FTC\u0026rsquo;s High Court Loss,\u0026rdquo;\u0026nbsp;\u003cem\u003eLaw360\u003c/em\u003e, May 6, 2021.\u003c/li\u003e\n\u003cli\u003eQuoted in, \u0026ldquo;By the Numbers: 5 Practices That Could Drive Big Law in 2021,\u0026rdquo;\u0026nbsp;\u003cem\u003eBloomberg Law\u003c/em\u003e, December 23, 2020.\u003c/li\u003e\n\u003cli\u003eQuoted in, \u0026ldquo;\u0026lsquo;Hipster Antitrust\u0026rsquo; Comes for Joe Biden,\u0026rdquo;\u0026nbsp;\u003cem\u003eNew York Times\u003c/em\u003e, November 13, 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;A Watershed Moment? What Comes Next for the FTC in the Wake of AMG,\u0026rdquo;\u003cem\u003e\u0026nbsp;ABA Antitrust Magazine\u003c/em\u003e, August 9, 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The Intersection of Antitrust and the False Claims Act,\u0026rdquo;\u0026nbsp;\u003cem\u003eHeadnotes\u003c/em\u003e, Dallas Bar Association, June 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Unpacking the New FTC/DOJ Draft Vertical Merger Guidelines,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, March 9, 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Seventh Circuit Sets Up Potential Supreme Court Review of FTC Monetary Relief Authority,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, December 12, 2019.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Next Stop, Supreme Court? Seventh Circuit Goes Its Own Way on FTC\u0026rsquo;s Authority to Obtain Monetary Relief,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, September 3, 2019.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Taking Stock of FTC Cybersecurity Enforcement After the Equifax Settlement,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, August 7, 2019.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Ninth Circuit Judges Call for En Banc Review of FTC\u0026rsquo;s Authority to Obtain Monetary Relief,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, January 15, 2019.\u003c/li\u003e\n\u003cli\u003eCo-author, \u0026ldquo;Lessons from FTC\u0026rsquo;s Loss in, and Subsequent Abandonment of, DirecTV Advertising Case,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, October 23, 2018.\u003c/li\u003e\n\u003cli\u003eCo-author, \u0026ldquo;Are Disgorgement\u0026rsquo;s Days Numbered?\u0026nbsp;\u003cem\u003eKokesh v. SEC\u003c/em\u003e\u0026nbsp;May Foreshadow Curtailment of the FTC\u0026rsquo;s Authority to Obtain Monetary Relief,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Spring 2018.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Will\u0026nbsp;\u003cem\u003eKokesh v. FTC\u003c/em\u003e\u0026nbsp;Put a Kink in the Federal Trade Commission\u0026rsquo;s Disgorgement Hose?\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, July 10, 2017.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Antitrust Scrutiny of Pharmaceutical Product Hopping,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Fall 2013.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;When Mergers Become a Private Matter: An Updated Antitrust Primer,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Spring 2012.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Evaluating Mergers Between Potential Competitors Under the New Horizontal Merger Guidelines,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Fall 2010.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The Complexities of Litigating Generic Drug Exclusion Claims in the Antitrust Class Action Context,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Spring 2010.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Change?: Merger Enforcement in the New Administration,\u0026rdquo;\u0026nbsp;\u003cem\u003eThe Advocate\u003c/em\u003e, Summer 2009.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Deterring \u0026lsquo;Patent Ambush\u0026rsquo; in Standard Setting: Lessons from Rambus and Qualcomm,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Summer 2009.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The FTC\u0026rsquo;s N-Data Consent Order: A Missed Opportunity to Clarify Antitrust in Standard Setting,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Summer 2008.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Avoiding the Scarlet \u0026lsquo;S\u0026rsquo;: The Modern Challenges of Document Preservation and Destruction,\u0026rdquo;\u0026nbsp;\u003cem\u003eThe American Lawyer\u003c/em\u003e, June 2005.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The Art of Destruction,\u0026rdquo;\u0026nbsp;\u003cem\u003eThe American Lawyer\u003c/em\u003e, September 2004.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Standard Setting and Exclusionary Conduct: The Role of Antitrust in Policing Unilateral Abuses of a Standard-Setting Process,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust\u003c/em\u003e, 2004.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Administrative Litigation at the FTC: Past, Present, and Future,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 2003.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Noerr Immunity for Sponsoring Litigation: From Burlington Northern to Baltimore Scrap,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust\u003c/em\u003e, 2001.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Coping with the Antitrust Risks of Technological Integration,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 2000.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Disaggregation\u0026nbsp;of Antitrust Damages,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 1997.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Post-Chicago Economics,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 1995.\u003c/li\u003e\n\u003c/ul\u003e","slug":"sean-royall","email":"sroyall@kslaw.com","phone":null,"matters":["\u003cp\u003e\u003cstrong\u003eLitigation\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eIn re Namenda Indirect Purchaser Antitrust Litigation\u003c/em\u003e\u0026nbsp;(S.D.N.Y.) \u0026ndash; Represented Forest Labs. and affiliates in this still-ongoing indirect purchaser antitrust class action involving allegations of \u0026ldquo;product hopping\u0026rdquo; and a challenged \u0026ldquo;reverse payment\u0026rdquo; patent settlement.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eIn re Restasis Antitrust Litigation\u003c/em\u003e\u0026nbsp;(E.D.N.Y.) \u0026ndash; Served as lead counsel for Allergan in this consolidated MDL antitrust class action involving complex patent- and FDA-related monopolization claims predicated on allegations of delayed entry of generic drugs. Cases settled favorably for defendants after class certification and summary judgment briefing and arguments.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. ex rel. Silbersher v. Allergan\u003c/em\u003e\u0026nbsp;(N.D. Cal.) \u0026ndash; Served as lead counsel for Allergan in this False Claims Act litigation in which a private relator sought to assert claims of alleged fraud against the government predicated on a patent-related theory and assertions of delayed generic drug entry.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eIn re JUUL Labs., Inc. Antitrust Litigation\u003c/em\u003e\u0026nbsp;(N.D. Cal.) \u0026ndash; Served as lead antitrust counsel in this still-ongoing consolidated MDL antitrust class action challenging an allegedly unlawful agreement.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. v. AT\u0026amp;T\u0026nbsp;\u003c/em\u003e(C.D. Cal.) \u0026ndash; Served as lead antitrust counsel for AT\u0026amp;T in this suit in which DOJ asserted that AT\u0026amp;T\u0026rsquo;s DirecTV unit engaged in improper coordination and information sharing relating to pay TV distributors\u0026rsquo; negotiations with the provider of sports-related television content; case settled on highly favorable terms after full briefing of AT\u0026amp;T\u0026rsquo;s motion to dismiss.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eFTC v. Lending Club\u003c/em\u003e\u0026nbsp;(N.D. Cal.) \u0026ndash; Served as lead counsel for Lending Club in this suit in which the FTC asserted multiple consumer protection-based claims relating to Lending Club\u0026rsquo;s marketing and advertising practices and privacy-related compliance; argued summary and obtained partial victories; case settled favorably.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. v. AT\u0026amp;T\u003c/em\u003e\u0026nbsp;(D.D.C. \u0026amp; D.C. Cir.) \u0026ndash; Played an important role on the trial team in this landmark case in which AT\u0026amp;T defeated a DOJ antitrust challenge to the company\u0026rsquo;s US$85 billion acquisition of Time Warner, an outcome that was later affirmed on appeal in the D.C. Circuit.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSureShot v. Topgolf\u0026nbsp;\u003c/em\u003e(S.D. Tex. \u0026amp; 5th Cir.) \u0026ndash; Served as lead counsel for Topgolf in this antitrust suit asserting monopolization claims; obtained full dismissal of all claims by district court and unanimous affirmance.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eCipla v. Amgen\u003c/em\u003e\u0026nbsp;(D. Del. \u0026amp; 3d Cir.) \u0026ndash; Served as lead counsel for Amgen in this monopolization suit brought by a generic drug competitor; argued preliminary injunction motion and participated in later interlocutory appeal.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eShire v. Allergan\u003c/em\u003e\u0026nbsp;(D. N.J.) \u0026ndash; Served as lead counsel for Allergan in this competitor monopolization suit involving alleged bundling and exclusive dealing practices; argued successful motion to dismiss.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eHartig v. Allergan\u003c/em\u003e\u0026nbsp;(D. Del. \u0026amp; 3d Cir.) \u0026ndash; Served as lead counsel for Allergan in this putative antitrust class action asserting that Allergan delayed generic entry through alleged \u0026ldquo;product hopping\u0026rdquo;; argued successful motion to dismiss and later defended that ruling through oral argument before the Third Circuit; case was settled on highly favorable terms after remand to district court.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eApotex v. Allergan\u003c/em\u003e\u0026nbsp;(D. Del.) \u0026ndash; Served as lead counsel for Allergan in this competitor monopolization suit predicated on claims of unlawful \u0026ldquo;product hopping\u0026rdquo;; obtained highly favorable settlement after the close of fact and expert discovery.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAmphastar v. Sanofi-Aventis\u003c/em\u003e\u0026nbsp;(C.D. Cal.) \u0026ndash; Served as lead counsel for Sanofi in this competitor monopolization suit asserting patent- and FDA-related antitrust claims; successfully argued for dismissal of all claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. ex rel. Amphastar v. Sanofi-Aventis\u003c/em\u003e\u0026nbsp;(C.D. Cal \u0026amp; 9th Cir.) \u0026ndash; Served as lead counsel for Sanofi in this suit in which a competing generic drug company, having had its own antitrust claims dismissed, sought to assert related False Claims Act claims as a purported relator; case was fully dismissed by the district court and the outcome was affirmed by the Ninth Circuit.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eFTC v. Commerce Planet\u003c/em\u003e\u0026nbsp;(9th Cir.) \u0026ndash; Represented former Commerce Planet CEO in this FTC consumer protection suit in which the client, represented by prior counsel, was subjected to a judgment with significant personal liability.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eStanwood v. Mary Kay Cosmetics\u003c/em\u003e\u0026nbsp;(C.D. Cal.) \u0026ndash; Served as lead counsel for Mary Kay in this putative class action case alleging fraud and unfair competition relating to the company\u0026rsquo;s prior participation in industry pledge not to conduct animal-based testing; obtained full dismissal of all claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAvery Dennison v. 3M Corp.\u003c/em\u003e\u0026nbsp;(D. Minn.) \u0026ndash; Served as lead antitrust counsel for 3M in this competitor suit alleging that 3M monopolized markets through wrongful patent-related conduct in the context of industry standard-setting activities; case settled on highly favorable terms following the close of fact and expert discovery.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eIn re Wellbutrin XL Antitrust Litigation\u003c/em\u003e\u0026nbsp;(E.D. Pa.) \u0026ndash; Served as lead counsel for Biovail in this antitrust class action alleging patent-related monopolization and conspiracy claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eTodd v. Exxon, et al.\u0026nbsp;\u003c/em\u003e(S.D.N.Y.) \u0026ndash; Served as lead antitrust counsel for Phillips Petroleum in this putative antitrust class action alleging conspiracy claims based on asserted improper sharing of salary and benefits information.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eNeon Systems v. BMC Software\u003c/em\u003e\u0026nbsp;(Tex. Civ.) \u0026ndash; Served as lead antitrust counsel for BMC Software in this competitor suit alleging that BMC had monopolized markets through unlawful pricing and bundling practices; case settled favorably shortly before trial.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAtlantic Coast Airlines v. Mesa Airlines\u003c/em\u003e\u0026nbsp;(D.D.C.) \u0026ndash; Served as trial counsel for Atlantic Coast Airlines in this successful antitrust action obtaining a preliminary injunction barring United Airlines and Mesa Airlines from proceeding with a contemplated business arrangement.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eContinental Forge v. Sempra Energy\u003c/em\u003e\u0026nbsp;(Sup. Ct. Cal.) \u0026ndash; Represented Sempra Energy and affiliates in this suit alleging antitrust conspiracy claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eLonghorn Partners Pipeline Co. v. Holly Corp.\u003c/em\u003e\u0026nbsp;(W.D. Tex.) \u0026ndash; Represented Holly Corp. in this antitrust suit alleging monopolization of West Texas petroleum pipelines.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. v. AMR Corp.\u003c/em\u003e\u0026nbsp;(D. Kansas) \u0026ndash; Represented American Airlines and parent AMR in this government antitrust suit alleging predatory pricing; case resolved through summary judgment for defendants.*\u003c/p\u003e","\u003cp\u003e\u003cem\u003eLitton Systems v. Honeywell\u003c/em\u003e\u0026nbsp;(C.D. Cal. \u0026amp; 9th Cir.) \u0026ndash; Represented Honeywell in this competitor monopolization suit alleging that Honeywell improperly excluded competition in the market for commercial avionics systems; successfully argued motion for directed verdict on majority of claims at issue.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eContinental Airlines v. American Airlines\u003c/em\u003e\u0026nbsp;(S.D. Tex.) \u0026ndash;Represented American Airlines in this suit alleging improper predatory pricing relating to American\u0026rsquo;s introduction of a new fare structure; obtained favorable jury verdict.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eGovernment Investigations\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eKurbo/WW Inc. \u0026ndash; Lead counsel for WW International and affiliate Kurbo in connection with FTC privacy (COPPA) investigation and settlement.\u003c/p\u003e","\u003cp\u003eGoogle/Fitbit \u0026ndash; Counsel for Fitbit in connection with DOJ investigation of Google\u0026rsquo;s successful US$2.1 billion acquisition of Fitbit.\u003c/p\u003e","\u003cp\u003eAT\u0026amp;T/Time Warner \u0026ndash; Counsel for AT\u0026amp;T in connection with DOJ investigation of the company\u0026rsquo;s successful US$85 billion acquisition of Time Warner.\u003c/p\u003e","\u003cp\u003eAT\u0026amp;T/DirecTV \u0026ndash; Counsel for AT\u0026amp;T in connection with DOJ investigation of the company\u0026rsquo;s successful US$48 billion acquisition of DirecTV.\u003c/p\u003e","\u003cp\u003eFacebook \u0026ndash; Lead counsel for Facebook in connection with FTC investigation relating to compliance with prior 2012 consent order prescribing certain privacy-related standards and practices; also lead counsel for the company in connection with the prior 2012 FTC privacy investigation.\u003c/p\u003e","\u003cp\u003eBazaarvoice \u0026ndash; Lead counsel for Bazaarvoice relating to DOJ antitrust and order compliance investigations.\u003c/p\u003e","\u003cp\u003eTicketmaster/LiveNation \u0026ndash; Lead counsel for Ticketmaster in connection with DOJ investigation of the company\u0026rsquo;s US$2.5 billion acquisition of LiveNation.\u003c/p\u003e","\u003cp\u003eWilliams Cos. \u0026ndash; Lead antitrust counsel for Williams in connection with proposed US$38 billion acquisition by Energy Transfer Equity LP.\u003c/p\u003e","\u003cp\u003eLeon Max/Max Studios \u0026ndash; Lead counsel for Max Studios in connection with FTC investigation of asserted violations of prior FTC consent order imposing restrictions on advertising of textile content of retail garments.\u003c/p\u003e","\u003cp\u003eValueClick \u0026ndash; Lead counsel for ValueClick in connection with FTC consumer protection claims involving various privacy and online advertising issues.\u003c/p\u003e","\u003cp\u003eAllergan \u0026ndash; Lead counsel for Allergan in connection with FTC investigation of the company\u0026rsquo;s successful US$3.2 billion acquisition of Inamed Corp.\u003c/p\u003e","\u003cp\u003eWatson Wyatt \u0026ndash; Lead counsel for Watson Wyatt in connection with DOJ investigation of the company\u0026rsquo;s successful US$3.5 billion acquisition of Towers Perrin.\u003c/p\u003e","\u003cp\u003eUnited Defense \u0026ndash; Lead counsel for United Defense in DOJ investigation of BAe\u0026rsquo;s successful US$4.2 billion acquisition of UDI.\u003c/p\u003e","\u003cp\u003eAncestry.com \u0026ndash; Lead counsel for Ancestry.com in connection with FTC investigation of the company\u0026rsquo;s successful acquisition of Archive.com.\u003c/p\u003e","\u003cp\u003eEndocare \u0026ndash; Lead counsel for Endocare in connection with FTC investigation of proposed merger with Galil Medical.\u003c/p\u003e","\u003cp\u003eDiedrichCoffee \u0026ndash; Lead counsel for Diedrich in FTC investigation of successful merger with Green Mountain Coffee Roasters.\u003c/p\u003e","\u003cp\u003eNumerous other representations as lead counsel in non-public government investigations, including many FTC consumer protection matters, where successful results leading to closures of the investigations caused them to remain non-public matters.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":129,"guid":"129.capabilities","index":0,"source":"capabilities"},{"id":5,"guid":"5.capabilities","index":1,"source":"capabilities"},{"id":11,"guid":"11.capabilities","index":2,"source":"capabilities"},{"id":6,"guid":"6.capabilities","index":3,"source":"capabilities"},{"id":118,"guid":"118.capabilities","index":4,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":5,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":6,"source":"capabilities"},{"id":102,"guid":"102.capabilities","index":7,"source":"capabilities"},{"id":1147,"guid":"1147.smart_tags","index":8,"source":"smartTags"},{"id":750,"guid":"750.smart_tags","index":9,"source":"smartTags"},{"id":1141,"guid":"1141.smart_tags","index":10,"source":"smartTags"},{"id":3,"guid":"3.capabilities","index":11,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":12,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":13,"source":"capabilities"},{"id":2,"guid":"2.capabilities","index":14,"source":"capabilities"},{"id":106,"guid":"106.capabilities","index":15,"source":"capabilities"},{"id":761,"guid":"761.smart_tags","index":16,"source":"smartTags"},{"id":765,"guid":"765.smart_tags","index":17,"source":"smartTags"},{"id":952,"guid":"952.smart_tags","index":18,"source":"smartTags"},{"id":1,"guid":"1.capabilities","index":19,"source":"capabilities"},{"id":1248,"guid":"1248.smart_tags","index":20,"source":"smartTags"}],"is_active":true,"last_name":"Royall","nick_name":"M. Sean","clerkships":[{"name":"Judicial Clerk, Patrick E. Higginbotham, U.S Court of Appeals, 5th Circuit","years_held":"1990 - 1991"}],"first_name":"M. Sean","title_rank":9999,"updated_by":202,"law_schools":[{"id":2174,"meta":{"degree":"J.D.","honors":"cum laude, Law Review","is_law_school":"1","graduation_date":"1990-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"","name_suffix":"","recognitions":[{"title":"Ranked Band 1 for Antitrust, Texas","detail":"Chambers USA, 2007–2023"},{"title":"Top ranked for Antitrust USA","detail":"Chambers Global, 2020–2023"},{"title":"Named a “Litigation Star” for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work","detail":"Benchmark Litigation, 2023"},{"title":"Named “Highly Recommended (Texas)”","detail":"Global Competition Review, 2022"},{"title":"Named “Life Sciences Star” in Antitrust (2022) and Competition and Antitrust (2018–2019)","detail":"LMG Life Sciences"},{"title":"Named as one of “500 Leading Litigators in America”","detail":"Lawdragon, 2022 and 2024"},{"title":"Listed","detail":"Who’s Who Legal in Competition, 2021"},{"title":"Named “Litigation: Antitrust Lawyer of the Year”","detail":"The Best Lawyers in America, 2019"},{"title":"Named “Antitrust Lawyer of the Year”","detail":"The Best Lawyers in America, 2015 and 2018"},{"title":"Listed in “All-Star List”","detail":"BTI Services, 2017"},{"title":"Named “Mergers and Acquisitions and Antitrust Trailblazer”","detail":"National Law Journal, 2015"},{"title":"Named “National Antitrust MVP”","detail":"Law360, 2015"}],"linked_in_url":"https://www.linkedin.com/in/sean-royall-16964b232/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eSean Royall serves as the firm\u0026rsquo;s Global Practice Head for Antitrust and Consumer Protection. He has spent his entire career handling complex litigation matters and government investigations and is among the country\u0026rsquo;s most experienced and highly regarded antitrust lawyers. He focuses broadly on antitrust and consumer protection litigation, government investigations, and counseling, and is a highly experienced courtroom litigator with a stellar track record for winning high-stakes cases. Sean is equally effective navigating complex government investigations and advising clients on the details of a wide range of strategic antitrust and consumer protection issues.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eSean previously served at the Federal Trade Commission (FTC) as the Deputy Director of the FTC\u0026rsquo;s Bureau of Competition. His antitrust career, both in government and private practice, has included work on many major mergers and acquisitions, as well as lead roles in complex litigation matters that often intersect with other areas of law, including patent law, various federal regulatory regimes, consumer protection, and privacy. Sean has deep experience representing clients across a range of industries, including biopharma, healthcare, e-commerce, telecom, financial services, energy, transportation, software, and semiconductors. In addition\u0026nbsp;to his work on U.S. antitrust and consumer protection matters, Sean has worked and advised on many similar cases and investigations in Europe and other parts of the world.\u003c/p\u003e\n\u003cp\u003eWhile\u0026nbsp;in government, Sean\u0026nbsp;was the lead trial lawyer in the FTC\u0026rsquo;s landmark monopolization suit against computer chip maker Rambus Inc., a novel case that established new legal standards applicable to patent disclosure within industry standard-setting consortiums. More recently, Sean played an important role on the trial team for AT\u0026amp;T in the company\u0026rsquo;s victory over the Department of Justice\u0026rsquo;s antitrust challenge to AT\u0026amp;T\u0026rsquo;s US$85 billion acquisition of Time Warner. In addition to his trial experience, Sean has successfully argued appeals in courts around the country.\u003c/p\u003e\n\u003cp\u003eSean also has a nationally prominent reputation for his work in the consumer protection area, where he has particularly deep experience handling FTC investigations and associated litigation focused on advertising, marketing, privacy, and data security issues. In 2018-19, for example, Sean served as lead counsel for Facebook in connection with the FTC\u0026rsquo;s extensive privacy-related investigation and subsequent settlement. He brings to this area of his practice deep knowledge of applicable law and agency practice, as well as the skills of an accomplished litigator.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eFor well more than a decade, Sean has been given a Band 1 ranking by\u0026nbsp;\u003cem\u003eChambers USA\u0026nbsp;\u003c/em\u003e(2007-2025)\u003cem\u003e,\u0026nbsp;\u003c/em\u003ewhich has described him as \u0026ldquo;top of the field,\u0026rdquo; \u0026ldquo;a star in the antitrust world both in counseling and litigation,\u0026rdquo; and an \u0026ldquo;extremely talented lawyer and exceptional litigator.\u0026rdquo;\u003c/p\u003e\n\u003cp\u003eSean\u0026rsquo;s other recognitions include being ranked in\u0026nbsp;\u003cem\u003eChambers Global\u003c/em\u003e\u0026nbsp;for Antitrust \u0026ndash; USA (2020-2023); endorsed as \u0026ldquo;Highly Recommended (Texas)\u0026rdquo; by\u0026nbsp;\u003cem\u003eGlobal Competition Review\u003c/em\u003e\u0026nbsp;(2025); named a \u0026ldquo;Litigation Star\u0026rdquo; for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work by\u0026nbsp;\u003cem\u003eBenchmark Litigation\u003c/em\u003e\u0026nbsp;(2023). He is named by \u003cem\u003eLexology\u003c/em\u003e as a \"Competition Thought Leader\" (2025);\u0026nbsp;\u003cem\u003e\u0026nbsp;The Best Lawyers in America\u003c/em\u003e\u0026nbsp;as \u0026ldquo;Antitrust Lawyer of the Year\u0026rdquo; (2015, 2018); and \u003cem\u003eThe Best Lawyers in America\u003c/em\u003e\u0026nbsp;as \u0026ldquo;Litigation: Antitrust Lawyer of the Year\u0026rdquo; (2019). He has also been named to the \u0026ldquo;All-Star List\u0026rdquo; by BTI Services (2017) and deemed a \u0026ldquo;National Antitrust MVP\u0026rdquo; by\u0026nbsp;\u003cem\u003eLaw360\u003c/em\u003e\u0026nbsp;(2015); a \u0026ldquo;Mergers and Acquisitions and Antitrust Trailblazer\u0026rdquo; by\u0026nbsp;\u003cem\u003eNational Law Journal\u003c/em\u003e\u0026nbsp;(2015); and a \u0026ldquo;Life Sciences Star\u0026rdquo; in Antitrust (2022) and Competition and Antitrust (2018\u0026ndash;2019) by\u0026nbsp;\u003cem\u003eLMG Life Sciences\u003c/em\u003e. For the fourth year in a row, Sean was also named by \u003cem\u003eLawdragon \u003c/em\u003eas one of the \"500 Leading Litigators in America.\"\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublications\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSean has written extensively on a wide range of topics relevant to, among other things, antitrust law and policy, consumer protection, privacy, FTC process and remedies, class action antitrust litigation, pharmaceutical antitrust, and standard setting. Sean previously served as Editorial Chair of the ABA\u0026rsquo;s\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, and as an editor of the ABA\u0026rsquo;s\u0026nbsp;\u003cem\u003eAntitrust\u003c/em\u003e\u0026nbsp;magazine and of the Von Kalinowski treatise on\u0026nbsp;\u003cem\u003eAntitrust Laws and Trade Regulation\u003c/em\u003e.\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eAuthor, \u0026ldquo;A Google Breakup Would Serve Progressive Aims and Punish Business,\u0026rdquo; \u003cem\u003eBloomberg Law\u003c/em\u003e, October 5, 2023.\u003c/li\u003e\n\u003cli\u003eAuthor, \u0026ldquo;The FTC\u0026rsquo;s Punctuated Equilibrium,\u0026rdquo; \u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, September 2023.\u003c/li\u003e\n\u003cli\u003eAuthor, \u0026ldquo;The FTC\u0026rsquo;s COPPA Conundrum: Ambiguities in the Rule and a Dearth of Authoritative Guidance Leave the Agency Vulnerable to Legal Challenges\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, September 9, 2022.\u003c/li\u003e\n\u003cli\u003eAuthor, \u0026ldquo;Antitrust and Consumer Protection at Last Converge,\u0026rdquo;\u0026nbsp;\u003cem\u003eCorporate Counsel\u003c/em\u003e, April 27, 2022.\u003c/li\u003e\n\u003cli\u003eQuoted in, \u0026ldquo;CFPB May Fill Enforcement Gap After FTC\u0026rsquo;s High Court Loss,\u0026rdquo;\u0026nbsp;\u003cem\u003eLaw360\u003c/em\u003e, May 6, 2021.\u003c/li\u003e\n\u003cli\u003eQuoted in, \u0026ldquo;By the Numbers: 5 Practices That Could Drive Big Law in 2021,\u0026rdquo;\u0026nbsp;\u003cem\u003eBloomberg Law\u003c/em\u003e, December 23, 2020.\u003c/li\u003e\n\u003cli\u003eQuoted in, \u0026ldquo;\u0026lsquo;Hipster Antitrust\u0026rsquo; Comes for Joe Biden,\u0026rdquo;\u0026nbsp;\u003cem\u003eNew York Times\u003c/em\u003e, November 13, 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;A Watershed Moment? What Comes Next for the FTC in the Wake of AMG,\u0026rdquo;\u003cem\u003e\u0026nbsp;ABA Antitrust Magazine\u003c/em\u003e, August 9, 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The Intersection of Antitrust and the False Claims Act,\u0026rdquo;\u0026nbsp;\u003cem\u003eHeadnotes\u003c/em\u003e, Dallas Bar Association, June 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Unpacking the New FTC/DOJ Draft Vertical Merger Guidelines,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, March 9, 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Seventh Circuit Sets Up Potential Supreme Court Review of FTC Monetary Relief Authority,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, December 12, 2019.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Next Stop, Supreme Court? Seventh Circuit Goes Its Own Way on FTC\u0026rsquo;s Authority to Obtain Monetary Relief,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, September 3, 2019.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Taking Stock of FTC Cybersecurity Enforcement After the Equifax Settlement,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, August 7, 2019.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Ninth Circuit Judges Call for En Banc Review of FTC\u0026rsquo;s Authority to Obtain Monetary Relief,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, January 15, 2019.\u003c/li\u003e\n\u003cli\u003eCo-author, \u0026ldquo;Lessons from FTC\u0026rsquo;s Loss in, and Subsequent Abandonment of, DirecTV Advertising Case,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, October 23, 2018.\u003c/li\u003e\n\u003cli\u003eCo-author, \u0026ldquo;Are Disgorgement\u0026rsquo;s Days Numbered?\u0026nbsp;\u003cem\u003eKokesh v. SEC\u003c/em\u003e\u0026nbsp;May Foreshadow Curtailment of the FTC\u0026rsquo;s Authority to Obtain Monetary Relief,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Spring 2018.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Will\u0026nbsp;\u003cem\u003eKokesh v. FTC\u003c/em\u003e\u0026nbsp;Put a Kink in the Federal Trade Commission\u0026rsquo;s Disgorgement Hose?\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, July 10, 2017.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Antitrust Scrutiny of Pharmaceutical Product Hopping,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Fall 2013.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;When Mergers Become a Private Matter: An Updated Antitrust Primer,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Spring 2012.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Evaluating Mergers Between Potential Competitors Under the New Horizontal Merger Guidelines,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Fall 2010.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The Complexities of Litigating Generic Drug Exclusion Claims in the Antitrust Class Action Context,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Spring 2010.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Change?: Merger Enforcement in the New Administration,\u0026rdquo;\u0026nbsp;\u003cem\u003eThe Advocate\u003c/em\u003e, Summer 2009.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Deterring \u0026lsquo;Patent Ambush\u0026rsquo; in Standard Setting: Lessons from Rambus and Qualcomm,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Summer 2009.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The FTC\u0026rsquo;s N-Data Consent Order: A Missed Opportunity to Clarify Antitrust in Standard Setting,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Summer 2008.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Avoiding the Scarlet \u0026lsquo;S\u0026rsquo;: The Modern Challenges of Document Preservation and Destruction,\u0026rdquo;\u0026nbsp;\u003cem\u003eThe American Lawyer\u003c/em\u003e, June 2005.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The Art of Destruction,\u0026rdquo;\u0026nbsp;\u003cem\u003eThe American Lawyer\u003c/em\u003e, September 2004.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Standard Setting and Exclusionary Conduct: The Role of Antitrust in Policing Unilateral Abuses of a Standard-Setting Process,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust\u003c/em\u003e, 2004.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Administrative Litigation at the FTC: Past, Present, and Future,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 2003.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Noerr Immunity for Sponsoring Litigation: From Burlington Northern to Baltimore Scrap,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust\u003c/em\u003e, 2001.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Coping with the Antitrust Risks of Technological Integration,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 2000.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Disaggregation\u0026nbsp;of Antitrust Damages,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 1997.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Post-Chicago Economics,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 1995.\u003c/li\u003e\n\u003c/ul\u003e","matters":["\u003cp\u003e\u003cstrong\u003eLitigation\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eIn re Namenda Indirect Purchaser Antitrust Litigation\u003c/em\u003e\u0026nbsp;(S.D.N.Y.) \u0026ndash; Represented Forest Labs. and affiliates in this still-ongoing indirect purchaser antitrust class action involving allegations of \u0026ldquo;product hopping\u0026rdquo; and a challenged \u0026ldquo;reverse payment\u0026rdquo; patent settlement.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eIn re Restasis Antitrust Litigation\u003c/em\u003e\u0026nbsp;(E.D.N.Y.) \u0026ndash; Served as lead counsel for Allergan in this consolidated MDL antitrust class action involving complex patent- and FDA-related monopolization claims predicated on allegations of delayed entry of generic drugs. Cases settled favorably for defendants after class certification and summary judgment briefing and arguments.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. ex rel. Silbersher v. Allergan\u003c/em\u003e\u0026nbsp;(N.D. Cal.) \u0026ndash; Served as lead counsel for Allergan in this False Claims Act litigation in which a private relator sought to assert claims of alleged fraud against the government predicated on a patent-related theory and assertions of delayed generic drug entry.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eIn re JUUL Labs., Inc. Antitrust Litigation\u003c/em\u003e\u0026nbsp;(N.D. Cal.) \u0026ndash; Served as lead antitrust counsel in this still-ongoing consolidated MDL antitrust class action challenging an allegedly unlawful agreement.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. v. AT\u0026amp;T\u0026nbsp;\u003c/em\u003e(C.D. Cal.) \u0026ndash; Served as lead antitrust counsel for AT\u0026amp;T in this suit in which DOJ asserted that AT\u0026amp;T\u0026rsquo;s DirecTV unit engaged in improper coordination and information sharing relating to pay TV distributors\u0026rsquo; negotiations with the provider of sports-related television content; case settled on highly favorable terms after full briefing of AT\u0026amp;T\u0026rsquo;s motion to dismiss.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eFTC v. Lending Club\u003c/em\u003e\u0026nbsp;(N.D. Cal.) \u0026ndash; Served as lead counsel for Lending Club in this suit in which the FTC asserted multiple consumer protection-based claims relating to Lending Club\u0026rsquo;s marketing and advertising practices and privacy-related compliance; argued summary and obtained partial victories; case settled favorably.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. v. AT\u0026amp;T\u003c/em\u003e\u0026nbsp;(D.D.C. \u0026amp; D.C. Cir.) \u0026ndash; Played an important role on the trial team in this landmark case in which AT\u0026amp;T defeated a DOJ antitrust challenge to the company\u0026rsquo;s US$85 billion acquisition of Time Warner, an outcome that was later affirmed on appeal in the D.C. Circuit.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSureShot v. Topgolf\u0026nbsp;\u003c/em\u003e(S.D. Tex. \u0026amp; 5th Cir.) \u0026ndash; Served as lead counsel for Topgolf in this antitrust suit asserting monopolization claims; obtained full dismissal of all claims by district court and unanimous affirmance.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eCipla v. Amgen\u003c/em\u003e\u0026nbsp;(D. Del. \u0026amp; 3d Cir.) \u0026ndash; Served as lead counsel for Amgen in this monopolization suit brought by a generic drug competitor; argued preliminary injunction motion and participated in later interlocutory appeal.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eShire v. Allergan\u003c/em\u003e\u0026nbsp;(D. N.J.) \u0026ndash; Served as lead counsel for Allergan in this competitor monopolization suit involving alleged bundling and exclusive dealing practices; argued successful motion to dismiss.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eHartig v. Allergan\u003c/em\u003e\u0026nbsp;(D. Del. \u0026amp; 3d Cir.) \u0026ndash; Served as lead counsel for Allergan in this putative antitrust class action asserting that Allergan delayed generic entry through alleged \u0026ldquo;product hopping\u0026rdquo;; argued successful motion to dismiss and later defended that ruling through oral argument before the Third Circuit; case was settled on highly favorable terms after remand to district court.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eApotex v. Allergan\u003c/em\u003e\u0026nbsp;(D. Del.) \u0026ndash; Served as lead counsel for Allergan in this competitor monopolization suit predicated on claims of unlawful \u0026ldquo;product hopping\u0026rdquo;; obtained highly favorable settlement after the close of fact and expert discovery.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAmphastar v. Sanofi-Aventis\u003c/em\u003e\u0026nbsp;(C.D. Cal.) \u0026ndash; Served as lead counsel for Sanofi in this competitor monopolization suit asserting patent- and FDA-related antitrust claims; successfully argued for dismissal of all claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. ex rel. Amphastar v. Sanofi-Aventis\u003c/em\u003e\u0026nbsp;(C.D. Cal \u0026amp; 9th Cir.) \u0026ndash; Served as lead counsel for Sanofi in this suit in which a competing generic drug company, having had its own antitrust claims dismissed, sought to assert related False Claims Act claims as a purported relator; case was fully dismissed by the district court and the outcome was affirmed by the Ninth Circuit.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eFTC v. Commerce Planet\u003c/em\u003e\u0026nbsp;(9th Cir.) \u0026ndash; Represented former Commerce Planet CEO in this FTC consumer protection suit in which the client, represented by prior counsel, was subjected to a judgment with significant personal liability.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eStanwood v. Mary Kay Cosmetics\u003c/em\u003e\u0026nbsp;(C.D. Cal.) \u0026ndash; Served as lead counsel for Mary Kay in this putative class action case alleging fraud and unfair competition relating to the company\u0026rsquo;s prior participation in industry pledge not to conduct animal-based testing; obtained full dismissal of all claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAvery Dennison v. 3M Corp.\u003c/em\u003e\u0026nbsp;(D. Minn.) \u0026ndash; Served as lead antitrust counsel for 3M in this competitor suit alleging that 3M monopolized markets through wrongful patent-related conduct in the context of industry standard-setting activities; case settled on highly favorable terms following the close of fact and expert discovery.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eIn re Wellbutrin XL Antitrust Litigation\u003c/em\u003e\u0026nbsp;(E.D. Pa.) \u0026ndash; Served as lead counsel for Biovail in this antitrust class action alleging patent-related monopolization and conspiracy claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eTodd v. Exxon, et al.\u0026nbsp;\u003c/em\u003e(S.D.N.Y.) \u0026ndash; Served as lead antitrust counsel for Phillips Petroleum in this putative antitrust class action alleging conspiracy claims based on asserted improper sharing of salary and benefits information.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eNeon Systems v. BMC Software\u003c/em\u003e\u0026nbsp;(Tex. Civ.) \u0026ndash; Served as lead antitrust counsel for BMC Software in this competitor suit alleging that BMC had monopolized markets through unlawful pricing and bundling practices; case settled favorably shortly before trial.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAtlantic Coast Airlines v. Mesa Airlines\u003c/em\u003e\u0026nbsp;(D.D.C.) \u0026ndash; Served as trial counsel for Atlantic Coast Airlines in this successful antitrust action obtaining a preliminary injunction barring United Airlines and Mesa Airlines from proceeding with a contemplated business arrangement.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eContinental Forge v. Sempra Energy\u003c/em\u003e\u0026nbsp;(Sup. Ct. Cal.) \u0026ndash; Represented Sempra Energy and affiliates in this suit alleging antitrust conspiracy claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eLonghorn Partners Pipeline Co. v. Holly Corp.\u003c/em\u003e\u0026nbsp;(W.D. Tex.) \u0026ndash; Represented Holly Corp. in this antitrust suit alleging monopolization of West Texas petroleum pipelines.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. v. AMR Corp.\u003c/em\u003e\u0026nbsp;(D. Kansas) \u0026ndash; Represented American Airlines and parent AMR in this government antitrust suit alleging predatory pricing; case resolved through summary judgment for defendants.*\u003c/p\u003e","\u003cp\u003e\u003cem\u003eLitton Systems v. Honeywell\u003c/em\u003e\u0026nbsp;(C.D. Cal. \u0026amp; 9th Cir.) \u0026ndash; Represented Honeywell in this competitor monopolization suit alleging that Honeywell improperly excluded competition in the market for commercial avionics systems; successfully argued motion for directed verdict on majority of claims at issue.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eContinental Airlines v. American Airlines\u003c/em\u003e\u0026nbsp;(S.D. Tex.) \u0026ndash;Represented American Airlines in this suit alleging improper predatory pricing relating to American\u0026rsquo;s introduction of a new fare structure; obtained favorable jury verdict.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eGovernment Investigations\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eKurbo/WW Inc. \u0026ndash; Lead counsel for WW International and affiliate Kurbo in connection with FTC privacy (COPPA) investigation and settlement.\u003c/p\u003e","\u003cp\u003eGoogle/Fitbit \u0026ndash; Counsel for Fitbit in connection with DOJ investigation of Google\u0026rsquo;s successful US$2.1 billion acquisition of Fitbit.\u003c/p\u003e","\u003cp\u003eAT\u0026amp;T/Time Warner \u0026ndash; Counsel for AT\u0026amp;T in connection with DOJ investigation of the company\u0026rsquo;s successful US$85 billion acquisition of Time Warner.\u003c/p\u003e","\u003cp\u003eAT\u0026amp;T/DirecTV \u0026ndash; Counsel for AT\u0026amp;T in connection with DOJ investigation of the company\u0026rsquo;s successful US$48 billion acquisition of DirecTV.\u003c/p\u003e","\u003cp\u003eFacebook \u0026ndash; Lead counsel for Facebook in connection with FTC investigation relating to compliance with prior 2012 consent order prescribing certain privacy-related standards and practices; also lead counsel for the company in connection with the prior 2012 FTC privacy investigation.\u003c/p\u003e","\u003cp\u003eBazaarvoice \u0026ndash; Lead counsel for Bazaarvoice relating to DOJ antitrust and order compliance investigations.\u003c/p\u003e","\u003cp\u003eTicketmaster/LiveNation \u0026ndash; Lead counsel for Ticketmaster in connection with DOJ investigation of the company\u0026rsquo;s US$2.5 billion acquisition of LiveNation.\u003c/p\u003e","\u003cp\u003eWilliams Cos. \u0026ndash; Lead antitrust counsel for Williams in connection with proposed US$38 billion acquisition by Energy Transfer Equity LP.\u003c/p\u003e","\u003cp\u003eLeon Max/Max Studios \u0026ndash; Lead counsel for Max Studios in connection with FTC investigation of asserted violations of prior FTC consent order imposing restrictions on advertising of textile content of retail garments.\u003c/p\u003e","\u003cp\u003eValueClick \u0026ndash; Lead counsel for ValueClick in connection with FTC consumer protection claims involving various privacy and online advertising issues.\u003c/p\u003e","\u003cp\u003eAllergan \u0026ndash; Lead counsel for Allergan in connection with FTC investigation of the company\u0026rsquo;s successful US$3.2 billion acquisition of Inamed Corp.\u003c/p\u003e","\u003cp\u003eWatson Wyatt \u0026ndash; Lead counsel for Watson Wyatt in connection with DOJ investigation of the company\u0026rsquo;s successful US$3.5 billion acquisition of Towers Perrin.\u003c/p\u003e","\u003cp\u003eUnited Defense \u0026ndash; Lead counsel for United Defense in DOJ investigation of BAe\u0026rsquo;s successful US$4.2 billion acquisition of UDI.\u003c/p\u003e","\u003cp\u003eAncestry.com \u0026ndash; Lead counsel for Ancestry.com in connection with FTC investigation of the company\u0026rsquo;s successful acquisition of Archive.com.\u003c/p\u003e","\u003cp\u003eEndocare \u0026ndash; Lead counsel for Endocare in connection with FTC investigation of proposed merger with Galil Medical.\u003c/p\u003e","\u003cp\u003eDiedrichCoffee \u0026ndash; Lead counsel for Diedrich in FTC investigation of successful merger with Green Mountain Coffee Roasters.\u003c/p\u003e","\u003cp\u003eNumerous other representations as lead counsel in non-public government investigations, including many FTC consumer protection matters, where successful results leading to closures of the investigations caused them to remain non-public matters.\u003c/p\u003e"],"recognitions":[{"title":"Ranked Band 1 for Antitrust, Texas","detail":"Chambers USA, 2007–2023"},{"title":"Top ranked for Antitrust USA","detail":"Chambers Global, 2020–2023"},{"title":"Named a “Litigation Star” for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work","detail":"Benchmark Litigation, 2023"},{"title":"Named “Highly Recommended (Texas)”","detail":"Global Competition Review, 2022"},{"title":"Named “Life Sciences Star” in Antitrust (2022) and Competition and Antitrust (2018–2019)","detail":"LMG Life Sciences"},{"title":"Named as one of “500 Leading Litigators in America”","detail":"Lawdragon, 2022 and 2024"},{"title":"Listed","detail":"Who’s Who Legal in Competition, 2021"},{"title":"Named “Litigation: Antitrust Lawyer of the Year”","detail":"The Best Lawyers in America, 2019"},{"title":"Named “Antitrust Lawyer of the Year”","detail":"The Best Lawyers in America, 2015 and 2018"},{"title":"Listed in “All-Star List”","detail":"BTI Services, 2017"},{"title":"Named “Mergers and Acquisitions and Antitrust Trailblazer”","detail":"National Law Journal, 2015"},{"title":"Named “National Antitrust MVP”","detail":"Law360, 2015"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":11010}]},"capability_group_id":3},"created_at":"2025-08-27T18:44:30.000Z","updated_at":"2025-08-27T18:44:30.000Z","searchable_text":"Royall{{ FIELD }}{:title=\u0026gt;\"Ranked Band 1 for Antitrust, Texas\", :detail=\u0026gt;\"Chambers USA, 2007–2023\"}{{ FIELD }}{:title=\u0026gt;\"Top ranked for Antitrust USA\", :detail=\u0026gt;\"Chambers Global, 2020–2023\"}{{ FIELD }}{:title=\u0026gt;\"Named a “Litigation Star” for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work\", :detail=\u0026gt;\"Benchmark Litigation, 2023\"}{{ FIELD }}{:title=\u0026gt;\"Named “Highly Recommended (Texas)”\", :detail=\u0026gt;\"Global Competition Review, 2022\"}{{ FIELD }}{:title=\u0026gt;\"Named “Life Sciences Star” in Antitrust (2022) and Competition and Antitrust (2018–2019)\", :detail=\u0026gt;\"LMG Life Sciences\"}{{ FIELD }}{:title=\u0026gt;\"Named as one of “500 Leading Litigators in America”\", :detail=\u0026gt;\"Lawdragon, 2022 and 2024\"}{{ FIELD }}{:title=\u0026gt;\"Listed\", :detail=\u0026gt;\"Who’s Who Legal in Competition, 2021\"}{{ FIELD }}{:title=\u0026gt;\"Named “Litigation: Antitrust Lawyer of the Year”\", :detail=\u0026gt;\"The Best Lawyers in America, 2019\"}{{ FIELD }}{:title=\u0026gt;\"Named “Antitrust Lawyer of the Year”\", :detail=\u0026gt;\"The Best Lawyers in America, 2015 and 2018\"}{{ FIELD }}{:title=\u0026gt;\"Listed in “All-Star List”\", :detail=\u0026gt;\"BTI Services, 2017\"}{{ FIELD }}{:title=\u0026gt;\"Named “Mergers and Acquisitions and Antitrust Trailblazer”\", :detail=\u0026gt;\"National Law Journal, 2015\"}{{ FIELD }}{:title=\u0026gt;\"Named “National Antitrust MVP”\", :detail=\u0026gt;\"Law360, 2015\"}{{ FIELD }}Litigation\nIn re Namenda Indirect Purchaser Antitrust Litigation (S.D.N.Y.) – Represented Forest Labs. and affiliates in this still-ongoing indirect purchaser antitrust class action involving allegations of “product hopping” and a challenged “reverse payment” patent settlement.{{ FIELD }}In re Restasis Antitrust Litigation (E.D.N.Y.) – Served as lead counsel for Allergan in this consolidated MDL antitrust class action involving complex patent- and FDA-related monopolization claims predicated on allegations of delayed entry of generic drugs. Cases settled favorably for defendants after class certification and summary judgment briefing and arguments.{{ FIELD }}U.S. ex rel. Silbersher v. Allergan (N.D. Cal.) – Served as lead counsel for Allergan in this False Claims Act litigation in which a private relator sought to assert claims of alleged fraud against the government predicated on a patent-related theory and assertions of delayed generic drug entry.{{ FIELD }}In re JUUL Labs., Inc. Antitrust Litigation (N.D. Cal.) – Served as lead antitrust counsel in this still-ongoing consolidated MDL antitrust class action challenging an allegedly unlawful agreement.{{ FIELD }}U.S. v. AT\u0026amp;T (C.D. Cal.) – Served as lead antitrust counsel for AT\u0026amp;T in this suit in which DOJ asserted that AT\u0026amp;T’s DirecTV unit engaged in improper coordination and information sharing relating to pay TV distributors’ negotiations with the provider of sports-related television content; case settled on highly favorable terms after full briefing of AT\u0026amp;T’s motion to dismiss.{{ FIELD }}FTC v. Lending Club (N.D. Cal.) – Served as lead counsel for Lending Club in this suit in which the FTC asserted multiple consumer protection-based claims relating to Lending Club’s marketing and advertising practices and privacy-related compliance; argued summary and obtained partial victories; case settled favorably.{{ FIELD }}U.S. v. AT\u0026amp;T (D.D.C. \u0026amp; D.C. Cir.) – Played an important role on the trial team in this landmark case in which AT\u0026amp;T defeated a DOJ antitrust challenge to the company’s US$85 billion acquisition of Time Warner, an outcome that was later affirmed on appeal in the D.C. Circuit.{{ FIELD }}SureShot v. Topgolf (S.D. Tex. \u0026amp; 5th Cir.) – Served as lead counsel for Topgolf in this antitrust suit asserting monopolization claims; obtained full dismissal of all claims by district court and unanimous affirmance.{{ FIELD }}Cipla v. Amgen (D. Del. \u0026amp; 3d Cir.) – Served as lead counsel for Amgen in this monopolization suit brought by a generic drug competitor; argued preliminary injunction motion and participated in later interlocutory appeal.{{ FIELD }}Shire v. Allergan (D. N.J.) – Served as lead counsel for Allergan in this competitor monopolization suit involving alleged bundling and exclusive dealing practices; argued successful motion to dismiss.{{ FIELD }}Hartig v. Allergan (D. Del. \u0026amp; 3d Cir.) – Served as lead counsel for Allergan in this putative antitrust class action asserting that Allergan delayed generic entry through alleged “product hopping”; argued successful motion to dismiss and later defended that ruling through oral argument before the Third Circuit; case was settled on highly favorable terms after remand to district court.{{ FIELD }}Apotex v. Allergan (D. Del.) – Served as lead counsel for Allergan in this competitor monopolization suit predicated on claims of unlawful “product hopping”; obtained highly favorable settlement after the close of fact and expert discovery.{{ FIELD }}Amphastar v. Sanofi-Aventis (C.D. Cal.) – Served as lead counsel for Sanofi in this competitor monopolization suit asserting patent- and FDA-related antitrust claims; successfully argued for dismissal of all claims.{{ FIELD }}U.S. ex rel. Amphastar v. Sanofi-Aventis (C.D. Cal \u0026amp; 9th Cir.) – Served as lead counsel for Sanofi in this suit in which a competing generic drug company, having had its own antitrust claims dismissed, sought to assert related False Claims Act claims as a purported relator; case was fully dismissed by the district court and the outcome was affirmed by the Ninth Circuit.{{ FIELD }}FTC v. Commerce Planet (9th Cir.) – Represented former Commerce Planet CEO in this FTC consumer protection suit in which the client, represented by prior counsel, was subjected to a judgment with significant personal liability.{{ FIELD }}Stanwood v. Mary Kay Cosmetics (C.D. Cal.) – Served as lead counsel for Mary Kay in this putative class action case alleging fraud and unfair competition relating to the company’s prior participation in industry pledge not to conduct animal-based testing; obtained full dismissal of all claims.{{ FIELD }}Avery Dennison v. 3M Corp. (D. Minn.) – Served as lead antitrust counsel for 3M in this competitor suit alleging that 3M monopolized markets through wrongful patent-related conduct in the context of industry standard-setting activities; case settled on highly favorable terms following the close of fact and expert discovery.{{ FIELD }}In re Wellbutrin XL Antitrust Litigation (E.D. Pa.) – Served as lead counsel for Biovail in this antitrust class action alleging patent-related monopolization and conspiracy claims.{{ FIELD }}Todd v. Exxon, et al. (S.D.N.Y.) – Served as lead antitrust counsel for Phillips Petroleum in this putative antitrust class action alleging conspiracy claims based on asserted improper sharing of salary and benefits information.{{ FIELD }}Neon Systems v. BMC Software (Tex. Civ.) – Served as lead antitrust counsel for BMC Software in this competitor suit alleging that BMC had monopolized markets through unlawful pricing and bundling practices; case settled favorably shortly before trial.{{ FIELD }}Atlantic Coast Airlines v. Mesa Airlines (D.D.C.) – Served as trial counsel for Atlantic Coast Airlines in this successful antitrust action obtaining a preliminary injunction barring United Airlines and Mesa Airlines from proceeding with a contemplated business arrangement.{{ FIELD }}Continental Forge v. Sempra Energy (Sup. Ct. Cal.) – Represented Sempra Energy and affiliates in this suit alleging antitrust conspiracy claims.{{ FIELD }}Longhorn Partners Pipeline Co. v. Holly Corp. (W.D. Tex.) – Represented Holly Corp. in this antitrust suit alleging monopolization of West Texas petroleum pipelines.{{ FIELD }}U.S. v. AMR Corp. (D. Kansas) – Represented American Airlines and parent AMR in this government antitrust suit alleging predatory pricing; case resolved through summary judgment for defendants.*{{ FIELD }}Litton Systems v. Honeywell (C.D. Cal. \u0026amp; 9th Cir.) – Represented Honeywell in this competitor monopolization suit alleging that Honeywell improperly excluded competition in the market for commercial avionics systems; successfully argued motion for directed verdict on majority of claims at issue.{{ FIELD }}Continental Airlines v. American Airlines (S.D. Tex.) –Represented American Airlines in this suit alleging improper predatory pricing relating to American’s introduction of a new fare structure; obtained favorable jury verdict.{{ FIELD }}Government Investigations\nKurbo/WW Inc. – Lead counsel for WW International and affiliate Kurbo in connection with FTC privacy (COPPA) investigation and settlement.{{ FIELD }}Google/Fitbit – Counsel for Fitbit in connection with DOJ investigation of Google’s successful US$2.1 billion acquisition of Fitbit.{{ FIELD }}AT\u0026amp;T/Time Warner – Counsel for AT\u0026amp;T in connection with DOJ investigation of the company’s successful US$85 billion acquisition of Time Warner.{{ FIELD }}AT\u0026amp;T/DirecTV – Counsel for AT\u0026amp;T in connection with DOJ investigation of the company’s successful US$48 billion acquisition of DirecTV.{{ FIELD }}Facebook – Lead counsel for Facebook in connection with FTC investigation relating to compliance with prior 2012 consent order prescribing certain privacy-related standards and practices; also lead counsel for the company in connection with the prior 2012 FTC privacy investigation.{{ FIELD }}Bazaarvoice – Lead counsel for Bazaarvoice relating to DOJ antitrust and order compliance investigations.{{ FIELD }}Ticketmaster/LiveNation – Lead counsel for Ticketmaster in connection with DOJ investigation of the company’s US$2.5 billion acquisition of LiveNation.{{ FIELD }}Williams Cos. – Lead antitrust counsel for Williams in connection with proposed US$38 billion acquisition by Energy Transfer Equity LP.{{ FIELD }}Leon Max/Max Studios – Lead counsel for Max Studios in connection with FTC investigation of asserted violations of prior FTC consent order imposing restrictions on advertising of textile content of retail garments.{{ FIELD }}ValueClick – Lead counsel for ValueClick in connection with FTC consumer protection claims involving various privacy and online advertising issues.{{ FIELD }}Allergan – Lead counsel for Allergan in connection with FTC investigation of the company’s successful US$3.2 billion acquisition of Inamed Corp.{{ FIELD }}Watson Wyatt – Lead counsel for Watson Wyatt in connection with DOJ investigation of the company’s successful US$3.5 billion acquisition of Towers Perrin.{{ FIELD }}United Defense – Lead counsel for United Defense in DOJ investigation of BAe’s successful US$4.2 billion acquisition of UDI.{{ FIELD }}Ancestry.com – Lead counsel for Ancestry.com in connection with FTC investigation of the company’s successful acquisition of Archive.com.{{ FIELD }}Endocare – Lead counsel for Endocare in connection with FTC investigation of proposed merger with Galil Medical.{{ FIELD }}DiedrichCoffee – Lead counsel for Diedrich in FTC investigation of successful merger with Green Mountain Coffee Roasters.{{ FIELD }}Numerous other representations as lead counsel in non-public government investigations, including many FTC consumer protection matters, where successful results leading to closures of the investigations caused them to remain non-public matters.{{ FIELD }}Sean Royall serves as the firm’s Global Practice Head for Antitrust and Consumer Protection. He has spent his entire career handling complex litigation matters and government investigations and is among the country’s most experienced and highly regarded antitrust lawyers. He focuses broadly on antitrust and consumer protection litigation, government investigations, and counseling, and is a highly experienced courtroom litigator with a stellar track record for winning high-stakes cases. Sean is equally effective navigating complex government investigations and advising clients on the details of a wide range of strategic antitrust and consumer protection issues.\nSean previously served at the Federal Trade Commission (FTC) as the Deputy Director of the FTC’s Bureau of Competition. His antitrust career, both in government and private practice, has included work on many major mergers and acquisitions, as well as lead roles in complex litigation matters that often intersect with other areas of law, including patent law, various federal regulatory regimes, consumer protection, and privacy. Sean has deep experience representing clients across a range of industries, including biopharma, healthcare, e-commerce, telecom, financial services, energy, transportation, software, and semiconductors. In addition to his work on U.S. antitrust and consumer protection matters, Sean has worked and advised on many similar cases and investigations in Europe and other parts of the world.\nWhile in government, Sean was the lead trial lawyer in the FTC’s landmark monopolization suit against computer chip maker Rambus Inc., a novel case that established new legal standards applicable to patent disclosure within industry standard-setting consortiums. More recently, Sean played an important role on the trial team for AT\u0026amp;T in the company’s victory over the Department of Justice’s antitrust challenge to AT\u0026amp;T’s US$85 billion acquisition of Time Warner. In addition to his trial experience, Sean has successfully argued appeals in courts around the country.\nSean also has a nationally prominent reputation for his work in the consumer protection area, where he has particularly deep experience handling FTC investigations and associated litigation focused on advertising, marketing, privacy, and data security issues. In 2018-19, for example, Sean served as lead counsel for Facebook in connection with the FTC’s extensive privacy-related investigation and subsequent settlement. He brings to this area of his practice deep knowledge of applicable law and agency practice, as well as the skills of an accomplished litigator. \nFor well more than a decade, Sean has been given a Band 1 ranking by Chambers USA (2007-2025), which has described him as “top of the field,” “a star in the antitrust world both in counseling and litigation,” and an “extremely talented lawyer and exceptional litigator.”\nSean’s other recognitions include being ranked in Chambers Global for Antitrust – USA (2020-2023); endorsed as “Highly Recommended (Texas)” by Global Competition Review (2025); named a “Litigation Star” for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work by Benchmark Litigation (2023). He is named by Lexology as a \"Competition Thought Leader\" (2025);  The Best Lawyers in America as “Antitrust Lawyer of the Year” (2015, 2018); and The Best Lawyers in America as “Litigation: Antitrust Lawyer of the Year” (2019). He has also been named to the “All-Star List” by BTI Services (2017) and deemed a “National Antitrust MVP” by Law360 (2015); a “Mergers and Acquisitions and Antitrust Trailblazer” by National Law Journal (2015); and a “Life Sciences Star” in Antitrust (2022) and Competition and Antitrust (2018–2019) by LMG Life Sciences. For the fourth year in a row, Sean was also named by Lawdragon as one of the \"500 Leading Litigators in America.\"\nPublications\nSean has written extensively on a wide range of topics relevant to, among other things, antitrust law and policy, consumer protection, privacy, FTC process and remedies, class action antitrust litigation, pharmaceutical antitrust, and standard setting. Sean previously served as Editorial Chair of the ABA’s Antitrust Law Journal, and as an editor of the ABA’s Antitrust magazine and of the Von Kalinowski treatise on Antitrust Laws and Trade Regulation.\n\nAuthor, “A Google Breakup Would Serve Progressive Aims and Punish Business,” Bloomberg Law, October 5, 2023.\nAuthor, “The FTC’s Punctuated Equilibrium,” ABA Antitrust Magazine, September 2023.\nAuthor, “The FTC’s COPPA Conundrum: Ambiguities in the Rule and a Dearth of Authoritative Guidance Leave the Agency Vulnerable to Legal Challenges” ABA Antitrust Magazine, September 9, 2022.\nAuthor, “Antitrust and Consumer Protection at Last Converge,” Corporate Counsel, April 27, 2022.\nQuoted in, “CFPB May Fill Enforcement Gap After FTC’s High Court Loss,” Law360, May 6, 2021.\nQuoted in, “By the Numbers: 5 Practices That Could Drive Big Law in 2021,” Bloomberg Law, December 23, 2020.\nQuoted in, “‘Hipster Antitrust’ Comes for Joe Biden,” New York Times, November 13, 2020.\n“A Watershed Moment? What Comes Next for the FTC in the Wake of AMG,” ABA Antitrust Magazine, August 9, 2020.\n“The Intersection of Antitrust and the False Claims Act,” Headnotes, Dallas Bar Association, June 2020.\n“Unpacking the New FTC/DOJ Draft Vertical Merger Guidelines,” WLF Legal Pulse, March 9, 2020.\n“Seventh Circuit Sets Up Potential Supreme Court Review of FTC Monetary Relief Authority,” ABA Antitrust Magazine, December 12, 2019.\n“Next Stop, Supreme Court? Seventh Circuit Goes Its Own Way on FTC’s Authority to Obtain Monetary Relief,” WLF Legal Pulse, September 3, 2019.\n“Taking Stock of FTC Cybersecurity Enforcement After the Equifax Settlement,” WLF Legal Pulse, August 7, 2019.\n“Ninth Circuit Judges Call for En Banc Review of FTC’s Authority to Obtain Monetary Relief,” WLF Legal Pulse, January 15, 2019.\nCo-author, “Lessons from FTC’s Loss in, and Subsequent Abandonment of, DirecTV Advertising Case,” WLF Legal Pulse, October 23, 2018.\nCo-author, “Are Disgorgement’s Days Numbered? Kokesh v. SEC May Foreshadow Curtailment of the FTC’s Authority to Obtain Monetary Relief,” ABA Antitrust Magazine, Spring 2018.\n“Will Kokesh v. FTC Put a Kink in the Federal Trade Commission’s Disgorgement Hose?” WLF Legal Pulse, July 10, 2017.\n“Antitrust Scrutiny of Pharmaceutical Product Hopping,” ABA Antitrust Magazine, Fall 2013.\n“When Mergers Become a Private Matter: An Updated Antitrust Primer,” ABA Antitrust Magazine, Spring 2012.\n“Evaluating Mergers Between Potential Competitors Under the New Horizontal Merger Guidelines,” ABA Antitrust Magazine, Fall 2010.\n“The Complexities of Litigating Generic Drug Exclusion Claims in the Antitrust Class Action Context,” ABA Antitrust Magazine, Spring 2010.\n“Change?: Merger Enforcement in the New Administration,” The Advocate, Summer 2009.\n“Deterring ‘Patent Ambush’ in Standard Setting: Lessons from Rambus and Qualcomm,” ABA Antitrust Magazine, Summer 2009.\n“The FTC’s N-Data Consent Order: A Missed Opportunity to Clarify Antitrust in Standard Setting,” ABA Antitrust Magazine, Summer 2008.\n“Avoiding the Scarlet ‘S’: The Modern Challenges of Document Preservation and Destruction,” The American Lawyer, June 2005.\n“The Art of Destruction,” The American Lawyer, September 2004.\n“Standard Setting and Exclusionary Conduct: The Role of Antitrust in Policing Unilateral Abuses of a Standard-Setting Process,” Antitrust, 2004.\n“Administrative Litigation at the FTC: Past, Present, and Future,” Antitrust Law Journal, 2003.\n“Noerr Immunity for Sponsoring Litigation: From Burlington Northern to Baltimore Scrap,” Antitrust, 2001.\n“Coping with the Antitrust Risks of Technological Integration,” Antitrust Law Journal, 2000.\n“Disaggregation of Antitrust Damages,” Antitrust Law Journal, 1997.\n“Post-Chicago Economics,” Antitrust Law Journal, 1995.\n Partner Ranked Band 1 for Antitrust, Texas Chambers USA, 2007–2023 Top ranked for Antitrust USA Chambers Global, 2020–2023 Named a “Litigation Star” for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work Benchmark Litigation, 2023 Named “Highly Recommended (Texas)” Global Competition Review, 2022 Named “Life Sciences Star” in Antitrust (2022) and Competition and Antitrust (2018–2019) LMG Life Sciences Named as one of “500 Leading Litigators in America” Lawdragon, 2022 and 2024 Listed Who’s Who Legal in Competition, 2021 Named “Litigation: Antitrust Lawyer of the Year” The Best Lawyers in America, 2019 Named “Antitrust Lawyer of the Year” The Best Lawyers in America, 2015 and 2018 Listed in “All-Star List” BTI Services, 2017 Named “Mergers and Acquisitions and Antitrust Trailblazer” National Law Journal, 2015 Named “National Antitrust MVP” Law360, 2015 Texas A\u0026amp;M University Texas A\u0026amp;M School of Law University of Chicago University of Chicago Law School U.S. Court of Appeals for the Federal Circuit U.S. Court of Appeals for the Third Circuit U.S. Court of Appeals for the Fifth Circuit U.S. District Court for the Northern District of Texas U.S. District Court for the Southern District of Texas District of Columbia Texas Senior Courts of England and Wales Current Practicing Certificate in Victoria (Australia) Judicial Clerk, Patrick E. Higginbotham, U.S Court of Appeals, 5th Circuit Litigation\nIn re Namenda Indirect Purchaser Antitrust Litigation (S.D.N.Y.) – Represented Forest Labs. and affiliates in this still-ongoing indirect purchaser antitrust class action involving allegations of “product hopping” and a challenged “reverse payment” patent settlement. In re Restasis Antitrust Litigation (E.D.N.Y.) – Served as lead counsel for Allergan in this consolidated MDL antitrust class action involving complex patent- and FDA-related monopolization claims predicated on allegations of delayed entry of generic drugs. Cases settled favorably for defendants after class certification and summary judgment briefing and arguments. U.S. ex rel. Silbersher v. Allergan (N.D. Cal.) – Served as lead counsel for Allergan in this False Claims Act litigation in which a private relator sought to assert claims of alleged fraud against the government predicated on a patent-related theory and assertions of delayed generic drug entry. In re JUUL Labs., Inc. Antitrust Litigation (N.D. Cal.) – Served as lead antitrust counsel in this still-ongoing consolidated MDL antitrust class action challenging an allegedly unlawful agreement. U.S. v. AT\u0026amp;T (C.D. Cal.) – Served as lead antitrust counsel for AT\u0026amp;T in this suit in which DOJ asserted that AT\u0026amp;T’s DirecTV unit engaged in improper coordination and information sharing relating to pay TV distributors’ negotiations with the provider of sports-related television content; case settled on highly favorable terms after full briefing of AT\u0026amp;T’s motion to dismiss. FTC v. Lending Club (N.D. Cal.) – Served as lead counsel for Lending Club in this suit in which the FTC asserted multiple consumer protection-based claims relating to Lending Club’s marketing and advertising practices and privacy-related compliance; argued summary and obtained partial victories; case settled favorably. U.S. v. AT\u0026amp;T (D.D.C. \u0026amp; D.C. Cir.) – Played an important role on the trial team in this landmark case in which AT\u0026amp;T defeated a DOJ antitrust challenge to the company’s US$85 billion acquisition of Time Warner, an outcome that was later affirmed on appeal in the D.C. Circuit. SureShot v. Topgolf (S.D. Tex. \u0026amp; 5th Cir.) – Served as lead counsel for Topgolf in this antitrust suit asserting monopolization claims; obtained full dismissal of all claims by district court and unanimous affirmance. Cipla v. Amgen (D. Del. \u0026amp; 3d Cir.) – Served as lead counsel for Amgen in this monopolization suit brought by a generic drug competitor; argued preliminary injunction motion and participated in later interlocutory appeal. Shire v. Allergan (D. N.J.) – Served as lead counsel for Allergan in this competitor monopolization suit involving alleged bundling and exclusive dealing practices; argued successful motion to dismiss. Hartig v. Allergan (D. Del. \u0026amp; 3d Cir.) – Served as lead counsel for Allergan in this putative antitrust class action asserting that Allergan delayed generic entry through alleged “product hopping”; argued successful motion to dismiss and later defended that ruling through oral argument before the Third Circuit; case was settled on highly favorable terms after remand to district court. Apotex v. Allergan (D. Del.) – Served as lead counsel for Allergan in this competitor monopolization suit predicated on claims of unlawful “product hopping”; obtained highly favorable settlement after the close of fact and expert discovery. Amphastar v. Sanofi-Aventis (C.D. Cal.) – Served as lead counsel for Sanofi in this competitor monopolization suit asserting patent- and FDA-related antitrust claims; successfully argued for dismissal of all claims. U.S. ex rel. Amphastar v. Sanofi-Aventis (C.D. Cal \u0026amp; 9th Cir.) – Served as lead counsel for Sanofi in this suit in which a competing generic drug company, having had its own antitrust claims dismissed, sought to assert related False Claims Act claims as a purported relator; case was fully dismissed by the district court and the outcome was affirmed by the Ninth Circuit. FTC v. Commerce Planet (9th Cir.) – Represented former Commerce Planet CEO in this FTC consumer protection suit in which the client, represented by prior counsel, was subjected to a judgment with significant personal liability. Stanwood v. Mary Kay Cosmetics (C.D. Cal.) – Served as lead counsel for Mary Kay in this putative class action case alleging fraud and unfair competition relating to the company’s prior participation in industry pledge not to conduct animal-based testing; obtained full dismissal of all claims. Avery Dennison v. 3M Corp. (D. Minn.) – Served as lead antitrust counsel for 3M in this competitor suit alleging that 3M monopolized markets through wrongful patent-related conduct in the context of industry standard-setting activities; case settled on highly favorable terms following the close of fact and expert discovery. In re Wellbutrin XL Antitrust Litigation (E.D. Pa.) – Served as lead counsel for Biovail in this antitrust class action alleging patent-related monopolization and conspiracy claims. Todd v. Exxon, et al. (S.D.N.Y.) – Served as lead antitrust counsel for Phillips Petroleum in this putative antitrust class action alleging conspiracy claims based on asserted improper sharing of salary and benefits information. Neon Systems v. BMC Software (Tex. Civ.) – Served as lead antitrust counsel for BMC Software in this competitor suit alleging that BMC had monopolized markets through unlawful pricing and bundling practices; case settled favorably shortly before trial. Atlantic Coast Airlines v. Mesa Airlines (D.D.C.) – Served as trial counsel for Atlantic Coast Airlines in this successful antitrust action obtaining a preliminary injunction barring United Airlines and Mesa Airlines from proceeding with a contemplated business arrangement. Continental Forge v. Sempra Energy (Sup. Ct. Cal.) – Represented Sempra Energy and affiliates in this suit alleging antitrust conspiracy claims. Longhorn Partners Pipeline Co. v. Holly Corp. (W.D. Tex.) – Represented Holly Corp. in this antitrust suit alleging monopolization of West Texas petroleum pipelines. U.S. v. AMR Corp. (D. Kansas) – Represented American Airlines and parent AMR in this government antitrust suit alleging predatory pricing; case resolved through summary judgment for defendants.* Litton Systems v. Honeywell (C.D. Cal. \u0026amp; 9th Cir.) – Represented Honeywell in this competitor monopolization suit alleging that Honeywell improperly excluded competition in the market for commercial avionics systems; successfully argued motion for directed verdict on majority of claims at issue. Continental Airlines v. American Airlines (S.D. Tex.) –Represented American Airlines in this suit alleging improper predatory pricing relating to American’s introduction of a new fare structure; obtained favorable jury verdict. Government Investigations\nKurbo/WW Inc. – Lead counsel for WW International and affiliate Kurbo in connection with FTC privacy (COPPA) investigation and settlement. Google/Fitbit – Counsel for Fitbit in connection with DOJ investigation of Google’s successful US$2.1 billion acquisition of Fitbit. AT\u0026amp;T/Time Warner – Counsel for AT\u0026amp;T in connection with DOJ investigation of the company’s successful US$85 billion acquisition of Time Warner. AT\u0026amp;T/DirecTV – Counsel for AT\u0026amp;T in connection with DOJ investigation of the company’s successful US$48 billion acquisition of DirecTV. Facebook – Lead counsel for Facebook in connection with FTC investigation relating to compliance with prior 2012 consent order prescribing certain privacy-related standards and practices; also lead counsel for the company in connection with the prior 2012 FTC privacy investigation. Bazaarvoice – Lead counsel for Bazaarvoice relating to DOJ antitrust and order compliance investigations. Ticketmaster/LiveNation – Lead counsel for Ticketmaster in connection with DOJ investigation of the company’s US$2.5 billion acquisition of LiveNation. Williams Cos. – Lead antitrust counsel for Williams in connection with proposed US$38 billion acquisition by Energy Transfer Equity LP. Leon Max/Max Studios – Lead counsel for Max Studios in connection with FTC investigation of asserted violations of prior FTC consent order imposing restrictions on advertising of textile content of retail garments. ValueClick – Lead counsel for ValueClick in connection with FTC consumer protection claims involving various privacy and online advertising issues. Allergan – Lead counsel for Allergan in connection with FTC investigation of the company’s successful US$3.2 billion acquisition of Inamed Corp. Watson Wyatt – Lead counsel for Watson Wyatt in connection with DOJ investigation of the company’s successful US$3.5 billion acquisition of Towers Perrin. United Defense – Lead counsel for United Defense in DOJ investigation of BAe’s successful US$4.2 billion acquisition of UDI. Ancestry.com – Lead counsel for Ancestry.com in connection with FTC investigation of the company’s successful acquisition of Archive.com. Endocare – Lead counsel for Endocare in connection with FTC investigation of proposed merger with Galil Medical. DiedrichCoffee – Lead counsel for Diedrich in FTC investigation of successful merger with Green Mountain Coffee Roasters. Numerous other representations as lead counsel in non-public government investigations, including many FTC consumer protection matters, where successful results leading to closures of the investigations caused them to remain non-public matters.","searchable_name":"M. Sean Royall","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":442618,"version":1,"owner_type":"Person","owner_id":6772,"payload":{"bio":"\u003cp\u003eJulia Richardson is a government relations advisor in King \u0026amp; Spalding\u0026rsquo;s Government Affairs \u0026amp; Public Policy Group. Julia specializes in developing and implementing policy and advocacy strategies in the legislative and executive branches and third-party policy engagement. She also focuses on building and maintaining relationships with congressional and executive branch\u0026nbsp;offices, businesses, trade associations, advocacy coalitions, and other groups. Prior to joining King \u0026amp; Spalding, Julia served as counsel and policy advisor to the Chairs of two Federal agencies:\u0026nbsp;the Federal Election Commission and the US Consumer Product Safety Commission (CPSC). She also served as the Director of the Office of Legislative Affairs at the CPSC. In addition to spending six years as the director of advocacy for a national trade association, Julia also previously worked as senior counsel for\u0026nbsp;the United States Senate Rules Committee and as an aide in the Florida Legislature.\u003c/p\u003e","slug":"julia-richardson","email":"jrichardson@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":23,"guid":"23.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":11,"guid":"11.capabilities","index":2,"source":"capabilities"}],"is_active":true,"last_name":"Richardson","nick_name":"Julia","clerkships":[],"first_name":"Julia","title_rank":9999,"updated_by":202,"law_schools":[{"id":755,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":null},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"E.","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":42,"translated_fields":{"en":{"bio":"\u003cp\u003eJulia Richardson is a government relations advisor in King \u0026amp; Spalding\u0026rsquo;s Government Affairs \u0026amp; Public Policy Group. Julia specializes in developing and implementing policy and advocacy strategies in the legislative and executive branches and third-party policy engagement. She also focuses on building and maintaining relationships with congressional and executive branch\u0026nbsp;offices, businesses, trade associations, advocacy coalitions, and other groups. Prior to joining King \u0026amp; Spalding, Julia served as counsel and policy advisor to the Chairs of two Federal agencies:\u0026nbsp;the Federal Election Commission and the US Consumer Product Safety Commission (CPSC). She also served as the Director of the Office of Legislative Affairs at the CPSC. In addition to spending six years as the director of advocacy for a national trade association, Julia also previously worked as senior counsel for\u0026nbsp;the United States Senate Rules Committee and as an aide in the Florida Legislature.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":12022}]},"capability_group_id":2},"created_at":"2025-11-12T15:37:06.000Z","updated_at":"2025-11-12T15:37:06.000Z","searchable_text":"Richardson{{ FIELD }}Julia Richardson is a government relations advisor in King \u0026amp; Spalding’s Government Affairs \u0026amp; Public Policy Group. Julia specializes in developing and implementing policy and advocacy strategies in the legislative and executive branches and third-party policy engagement. She also focuses on building and maintaining relationships with congressional and executive branch offices, businesses, trade associations, advocacy coalitions, and other groups. Prior to joining King \u0026amp; Spalding, Julia served as counsel and policy advisor to the Chairs of two Federal agencies: the Federal Election Commission and the US Consumer Product Safety Commission (CPSC). She also served as the Director of the Office of Legislative Affairs at the CPSC. In addition to spending six years as the director of advocacy for a national trade association, Julia also previously worked as senior counsel for the United States Senate Rules Committee and as an aide in the Florida Legislature. Government Relations Advisor University of Florida  Georgetown University Georgetown University Law Center District of Columbia Florida","searchable_name":"Julia E. Richardson","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null}]}}